<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Zynteglo, INN-betibeglogene autotemcel</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	text-transform:uppercase;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char";
	mso-style-link:"Comment Text Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char\,Comment Text Char2 Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,B Caption\,Bayer Caption\,Caption2\,IB Caption\,Medical Caption\,Table Caption";
	mso-style-link:"Caption Char\,B Caption Char\,Bayer Caption Char\,Caption2 Char\,IB Caption Char\,Medical Caption Char\,Table Caption Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:6.0pt;
	margin-right:.55in;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Calibri Light",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin:0in;
	line-height:normal;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#5A5A5A;
	letter-spacing:.75pt;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-indent:.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:8.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:107%;
	font-size:8.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	line-height:107%;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4472C4;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Segoe UI",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:normal;
	font-size:10.5pt;
	font-family:Consolas;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-style:italic;}
kbd
	{font-family:"Courier New";}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
span.MsoPlaceholderText
	{color:gray;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:10.0pt;
	margin-right:.6in;
	margin-bottom:8.0pt;
	margin-left:.6in;
	text-align:center;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:107%;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4472C4;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char\,Comment Text Char2 Char Char";
	mso-style-link:"Comment Text\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.documenttextoutlinenumbered, li.documenttextoutlinenumbered, div.documenttextoutlinenumbered
	{mso-style-name:"document text outline numbered";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar
	{mso-style-name:"C-Body Text Char";
	mso-style-link:"C-Body Text";
	font-family:"Times New Roman",serif;}
span.Mention1
	{mso-style-name:Mention1;
	color:#2B579A;
	background:#E6E6E6;}
p.C-Bullet, li.C-Bullet, div.C-Bullet
	{mso-style-name:C-Bullet;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-BulletIndented, li.C-BulletIndented, div.C-BulletIndented
	{mso-style-name:"C-Bullet Indented";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.tablefootnote, li.tablefootnote, div.tablefootnote
	{mso-style-name:"table footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.CaptionChar
	{mso-style-name:"Caption Char\,B Caption Char\,Bayer Caption Char\,Caption2 Char\,IB Caption Char\,Medical Caption Char\,Table Caption Char";
	mso-style-link:"Caption\,B Caption\,Bayer Caption\,Caption2\,IB Caption\,Medical Caption\,Table Caption";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.C-Hyperlink
	{mso-style-name:C-Hyperlink;
	color:blue;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;}
p.C-Heading1, li.C-Heading1, div.C-Heading1
	{mso-style-name:"C-Heading 1";
	mso-style-link:"C-Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Heading2, li.C-Heading2, div.C-Heading2
	{mso-style-name:"C-Heading 2";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading3, li.C-Heading3, div.C-Heading3
	{mso-style-name:"C-Heading 3";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading4, li.C-Heading4, div.C-Heading4
	{mso-style-name:"C-Heading 4";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading5, li.C-Heading5, div.C-Heading5
	{mso-style-name:"C-Heading 5";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading6, li.C-Heading6, div.C-Heading6
	{mso-style-name:"C-Heading 6";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.85in;
	text-indent:-.85in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-BodyTextIndent, li.C-BodyTextIndent, div.C-BodyTextIndent
	{mso-style-name:"C-Body Text Indent";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-TableHeader, li.C-TableHeader, div.C-TableHeader
	{mso-style-name:"C-Table Header";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-TableText, li.C-TableText, div.C-TableText
	{mso-style-name:"C-Table Text";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.C-TableFootnote, li.C-TableFootnote, div.C-TableFootnote
	{mso-style-name:"C-Table Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.1in;
	text-indent:-.1in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.C-TOCTitle, li.C-TOCTitle, div.C-TOCTitle
	{mso-style-name:"C-TOC Title";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:normal;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-CaptionContinued, li.C-CaptionContinued, div.C-CaptionContinued
	{mso-style-name:"C-Caption Continued";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-NumberedList, li.C-NumberedList, div.C-NumberedList
	{mso-style-name:"C-Numbered List";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-InstructionText, li.C-InstructionText, div.C-InstructionText
	{mso-style-name:"C-Instruction Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:red;
	display:none;}
p.C-Title, li.C-Title, div.C-Title
	{mso-style-name:C-Title;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:normal;
	font-size:18.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Header, li.C-Header, div.C-Header
	{mso-style-name:C-Header;
	margin:0in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-Footer, li.C-Footer, div.C-Footer
	{mso-style-name:C-Footer;
	margin:0in;
	text-align:right;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-Heading1non-numbered, li.C-Heading1non-numbered, div.C-Heading1non-numbered
	{mso-style-name:"C-Heading 1 \(non-numbered\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Heading2non-numbered, li.C-Heading2non-numbered, div.C-Heading2non-numbered
	{mso-style-name:"C-Heading 2 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading3non-numbered, li.C-Heading3non-numbered, div.C-Heading3non-numbered
	{mso-style-name:"C-Heading 3 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading4non-numbered, li.C-Heading4non-numbered, div.C-Heading4non-numbered
	{mso-style-name:"C-Heading 4 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading5non-numbered, li.C-Heading5non-numbered, div.C-Heading5non-numbered
	{mso-style-name:"C-Heading 5 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading6non-numbered, li.C-Heading6non-numbered, div.C-Heading6non-numbered
	{mso-style-name:"C-Heading 6 \(non-numbered\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.C-Heading1nopagebreak, li.C-Heading1nopagebreak, div.C-Heading1nopagebreak
	{mso-style-name:"C-Heading 1 \(no page break\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Heading1nopagebreak0, li.C-Heading1nopagebreak0, div.C-Heading1nopagebreak0
	{mso-style-name:"C-Heading 1 \(no page break\,non-numbered\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-AlphabeticList, li.C-AlphabeticList, div.C-AlphabeticList
	{mso-style-name:"C-Alphabetic List";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.C-Appendix, li.C-Appendix, div.C-Appendix
	{mso-style-name:C-Appendix;
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:99.35pt;
	text-indent:-99.35pt;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.C-TableCallout
	{mso-style-name:"C-Table Callout";
	font-family:"Times New Roman",serif;
	color:windowtext;
	position:relative;
	top:.5pt;
	letter-spacing:0pt;
	text-decoration:none none;
	vertical-align:super;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
p.C-AppendixNumbered, li.C-AppendixNumbered, div.C-AppendixNumbered
	{mso-style-name:"C-Appendix \(Numbered\)";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:99.35pt;
	text-indent:-99.35pt;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Alphabetic, li.C-Alphabetic, div.C-Alphabetic
	{mso-style-name:C-Alphabetic;
	mso-style-link:"C-Alphabetic Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:normal;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.C-Footnote, li.C-Footnote, div.C-Footnote
	{mso-style-name:C-Footnote;
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.C-Heading1Char
	{mso-style-name:"C-Heading 1 Char";
	mso-style-link:"C-Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.C-AlphabeticChar
	{mso-style-name:"C-Alphabetic Char";
	mso-style-link:C-Alphabetic;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.normaltextrun
	{mso-style-name:normaltextrun;}
span.spellingerror
	{mso-style-name:spellingerror;}
p.DisclaimerAgency, li.DisclaimerAgency, div.DisclaimerAgency
	{mso-style-name:"Disclaimer \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:0in;
	line-height:7.5pt;
	font-size:6.5pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;
	layout-grid-mode:line;}
p.DoccategoryheadingAgency, li.DoccategoryheadingAgency, div.DoccategoryheadingAgency
	{mso-style-name:"Doc category heading \(Agency\)";
	margin-top:28.35pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
p.DocsubtitleAgency, li.DocsubtitleAgency, div.DocsubtitleAgency
	{mso-style-name:"Doc subtitle \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:32.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.DoctitleAgency, li.DoctitleAgency, div.DoctitleAgency
	{mso-style-name:"Doc title \(Agency\)";
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:16.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;}
span.EndnotereferenceAgency
	{mso-style-name:"Endnote reference \(Agency\)";
	font-family:"Verdana",sans-serif;
	vertical-align:super;}
p.EndnotetextAgency, li.EndnotetextAgency, div.EndnotetextAgency
	{mso-style-name:"Endnote text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.FigureAgency, li.FigureAgency, div.FigureAgency
	{mso-style-name:"Figure \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:center;
	line-height:107%;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.FigureheadingAgency, li.FigureheadingAgency, div.FigureheadingAgency
	{mso-style-name:"Figure heading \(Agency\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.FooterblueAgency, li.FooterblueAgency, div.FooterblueAgency
	{mso-style-name:"Footer blue \(Agency\)";
	mso-style-link:"Footer blue \(Agency\) Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:6.5pt;
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
span.FooterblueAgencyCharChar
	{mso-style-name:"Footer blue \(Agency\) Char Char";
	mso-style-link:"Footer blue \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
span.FootnotereferenceAgency
	{mso-style-name:"Footnote reference \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:windowtext;
	vertical-align:super;}
p.FootnotetextAgency, li.FootnotetextAgency, div.FootnotetextAgency
	{mso-style-name:"Footnote text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.HeaderAgency, li.HeaderAgency, div.HeaderAgency
	{mso-style-name:"Header \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.Heading1Agency, li.Heading1Agency, div.Heading1Agency
	{mso-style-name:"Heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading2Agency, li.Heading2Agency, div.Heading2Agency
	{mso-style-name:"Heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading3Agency, li.Heading3Agency, div.Heading3Agency
	{mso-style-name:"Heading 3 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading4Agency, li.Heading4Agency, div.Heading4Agency
	{mso-style-name:"Heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading5Agency, li.Heading5Agency, div.Heading5Agency
	{mso-style-name:"Heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading6Agency, li.Heading6Agency, div.Heading6Agency
	{mso-style-name:"Heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading7Agency, li.Heading7Agency, div.Heading7Agency
	{mso-style-name:"Heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading8Agency, li.Heading8Agency, div.Heading8Agency
	{mso-style-name:"Heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading9Agency, li.Heading9Agency, div.Heading9Agency
	{mso-style-name:"Heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading1Agency, li.No-numheading1Agency, div.No-numheading1Agency
	{mso-style-name:"No-num heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.HeadingcentredAgency, li.HeadingcentredAgency, div.HeadingcentredAgency
	{mso-style-name:"Heading centred \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-align:center;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading4Agency, li.No-numheading4Agency, div.No-numheading4Agency
	{mso-style-name:"No-num heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading6Agency, li.No-numheading6Agency, div.No-numheading6Agency
	{mso-style-name:"No-num heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading7Agency, li.No-numheading7Agency, div.No-numheading7Agency
	{mso-style-name:"No-num heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading8Agency, li.No-numheading8Agency, div.No-numheading8Agency
	{mso-style-name:"No-num heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading9Agency, li.No-numheading9Agency, div.No-numheading9Agency
	{mso-style-name:"No-num heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-TOCheadingAgency, li.No-TOCheadingAgency, div.No-TOCheadingAgency
	{mso-style-name:"No-TOC heading \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.PagenumberAgency, li.PagenumberAgency, div.PagenumberAgency
	{mso-style-name:"Page number \(Agency\)";
	mso-style-link:"Page number \(Agency\) Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:right;
	line-height:107%;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.PagenumberAgencyCharChar
	{mso-style-name:"Page number \(Agency\) Char Char";
	mso-style-link:"Page number \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.RefAgency, li.RefAgency, div.RefAgency
	{mso-style-name:"Ref\. \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;}
p.SpecialcommentAgency, li.SpecialcommentAgency, div.SpecialcommentAgency
	{mso-style-name:"Special comment \(Agency\)";
	margin:0in;
	line-height:normal;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;
	color:red;}
p.TablefirstrowAgency, li.TablefirstrowAgency, div.TablefirstrowAgency
	{mso-style-name:"Table first row \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TableheadingAgency, li.TableheadingAgency, div.TableheadingAgency
	{mso-style-name:"Table heading \(Agency\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:107%;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableFigurenoteAgency, li.TableFigurenoteAgency, div.TableFigurenoteAgency
	{mso-style-name:"Table\/Figure note \(Agency\)";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Verdana",sans-serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Calibri",sans-serif;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	color:#605E5C;
	background:#E1DFDD;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Calibri",sans-serif;}
span.UnresolvedMention2
	{mso-style-name:"Unresolved Mention2";
	color:#605E5C;
	background:#E1DFDD;}
span.Mention2
	{mso-style-name:Mention2;
	color:#2B579A;
	background:#E1DFDD;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Calibri",sans-serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Calibri",sans-serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Calibri",sans-serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Calibri",sans-serif;
	color:green;
	font-style:normal;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Calibri",sans-serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Calibri",sans-serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Calibri",sans-serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Calibri",sans-serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Segoe UI",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Calibri",sans-serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:Consolas;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Calibri",sans-serif;
	color:#4472C4;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:Consolas;}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Calibri Light",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Calibri",sans-serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Calibri",sans-serif;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Calibri",sans-serif;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Calibri",sans-serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Calibri",sans-serif;
	color:#5A5A5A;
	letter-spacing:.75pt;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.9pt 70.55pt 56.9pt 70.55pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span style='font-family:"Times New Roman",serif'>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span style='font-family:"Times New Roman",serif'>SUMMARY
OF PRODUCT CHARACTERISTICS</span></b></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'><img width=20 height=20 id="Picture 2"
src="Zynteglo_clean_files/image001.png" alt="BT_1000x858px"></span><span
style='font-size:11.0pt'>This medicinal product is subject to additional
monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>Zynteglo 1.2&#8209;20&nbsp;&nbsp;10<sup>6</sup>&nbsp;cells/mL
dispersion for infusion. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span lang=FR
style='font-family:"Times New Roman",serif'>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=FR style='font-family:"Times New Roman",serif'>2.1 General description</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>Zynteglo (betibeglogene autotemcel) is a</span><span
lang=FR style='font-size:11.0pt'> genetically modified autologous CD34<sup>+ </sup>cell
enriched population that contains haematopoietic stem cells (HSC) transduced
with lentiviral vector (LVV) encoding the </span><span style='font-size:11.0pt'>&#946;</span><sup><span
lang=FR style='font-size:11.0pt'>A&#8209;T87Q</span></sup><span lang=FR
style='font-size:11.0pt'>&#8209;globin gene.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=FR
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>2.2 Qualitative and
quantitative composition</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The finished product is composed of one or more
infusion bags which contain a dispersion of <span style='color:black'>1.2&#8209;20&nbsp;&nbsp;</span>10<sup>6&nbsp;</sup><span
style='color:black'>cells/mL </span>suspended in cryopreservative solution<span
style='color:black'>. </span>Each infusion bag contains approximately
20&nbsp;mL of Zynteglo.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The quantitative information regarding strength, CD34<sup>+</sup>
cells, and dose for the medicinal product is provided in the Lot Information
Sheet. The Lot Information Sheet is included inside the lid of the cryoshipper
used to transport Zynteglo. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Excipient with known effect</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Each dose contains 391&#8209;1564&nbsp;mg sodium.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>For the full list of excipients, see section 6.1.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. PHARMACEUTICAL
FORM</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Dispersion for infusion.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>A clear to slightly cloudy, colourless to yellow or
pink dispersion.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4. CLINICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.1 Therapeutic
indication</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a
name="_Hlk500066939"><span style='font-size:11.0pt'>Zynteglo is indicated for
the treatment of patients 12 years and older with transfusion&#8209;dependent
&#946;&#8209;thalassaemia (TDT) who do not have a &#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype, for whom haematopoietic stem cell (HSC) transplantation is
appropriate but a human leukocyte antigen (HLA)&#8209;matched related HSC donor
is not available (see sections 4.4 and 5.1).</span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.2 Posology and
method of administration</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a
name="_Hlk497649473"><span style='font-size:11.0pt'>Zynteglo must be
administered in a qualified treatment centre by a physician(s) with experience
in HSC transplantation and in the treatment of patients with TDT. </span></a><a
name="_Hlk511314218"></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients are expected to enrol in a registry and will
be followed in the registry in order to better understand the long-term safety
and efficacy of Zynteglo. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Posology</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The minimum recommended dose of Zynteglo is
5.0&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup> cells/kg. In clinical
studies doses up to 20&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup>
cells/kg have been administered. The minimum recommended dose is the same for
adults and adolescents 12 years of age and older.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo is intended for autologous use (see section
4.4) and should only be administered once.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><i><span
style='font-family:"Times New Roman",serif'>Mobilisation and apheresis</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients are required to undergo HSC mobilisation
followed by apheresis to obtain CD34<sup>+</sup> stem cells which will be used
for medicinal product manufacturing (see section 5.1 for a description of the
mobilisation regimen used in clinical studies). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The minimum target number of CD34<sup>+</sup> cells to
be collected is 12&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup>&nbsp;cells/kg.
If the minimum dose of Zynteglo of 5.0&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup>&nbsp;cells/kg
is not met after initial medicinal product manufacturing, the patient may
undergo one or more additional cycles of mobilisation and apheresis, separated
by at least 14&nbsp;days, in order to obtain more cells for additional
manufacture.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>A back-up collection of CD34<sup>+</sup> stem cells of
&#8805;1.5&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup>&nbsp;cells/kg (if
collected by apheresis) or &gt;1.0&nbsp;&nbsp;10<sup>8</sup>&nbsp;TNC/kg (if
collected by bone marrow harvest) is required. These cells must be collected
from the patient and be cryopreserved prior to myeloablative conditioning and
infusion with Zynteglo. The back&#8209;up collection may be needed for rescue
treatment if there is: 1) compromise of Zynteglo after initiation of myeloablative
conditioning and before Zynteglo infusion, 2) primary engraftment failure, or
3) loss of engraftment after infusion with Zynteglo (see section 4.4). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><i><span
style='font-family:"Times New Roman",serif'>Pre-treatment conditioning </span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The treating physician should confirm that HSC
transplantation is appropriate for the patient before myeloablative
conditioning is initiated (see section 4.4). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt;color:black'>Full myeloablative conditioning must be
administered before infusion of Zynteglo (see section 5.1 for a description of
the myeloablative regimen used in clinical studies). </span><span
style='font-size:11.0pt'>It is recommended that patients maintain haemoglobin
(Hb) &#8805;11&nbsp;g/dL for at least 30&nbsp;days prior to mobilisation and
during myeloablative conditioning. Iron chelation should be stopped at least
7&nbsp;days prior to myeloablative conditioning. Prophylaxis for hepatic veno&#8209;occlusive
disease (VOD) is recommended. Prophylaxis for seizures should be considered
(see section 5.1 for a description of the prophylaxis regimen used in clinical
studies).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Myeloablative conditioning should not begin until the
complete set of infusion bag(s) constituting the dose of Zynteglo has been
received and stored at the administration site, and the availability of the
back-up collection is confirmed. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><i><span
style='font-family:"Times New Roman",serif'>Zynteglo administration</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>See Method of Administration below and section 6.6 for
details on Zynteglo administration and handling.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><i><span
style='font-family:"Times New Roman",serif'>After Zynteglo administration</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Any blood products required within the first
3&nbsp;months after Zynteglo infusion should be irradiated. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Restarting iron chelation after Zynteglo infusion may
be necessary and should be based on clinical practice (see sections 4.5 and
5.1). Phlebotomy can be used in lieu of iron chelation, when appropriate.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Special populations</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><i><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><i><span
style='font-size:11.0pt'>Elderly</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo has not been studied in patients
&gt;65&nbsp;years of age. HSC transplantation must be appropriate for a patient
with TDT to be treated with Zynteglo (see section 4.4). No dose adjustment is
required.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Renal impairment</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo has not been studied in patients with renal
impairment. Patients should be assessed for renal impairment defined as
creatinine clearance &#8804;70&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> to ensure
HSC transplantation is appropriate. No dose adjustment is required.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Hepatic impairment</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo has not been studied in patients with hepatic
impairment. Patients should be assessed for hepatic impairment to ensure HSC
transplantation is appropriate (see section 4.4.). No dose adjustment is
required.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Paediatric population</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The safety and efficacy of Zynteglo in children
&lt;12&nbsp;years of age have not yet been established. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Patients seropositive for human immunodeficiency virus
(HIV) or human T&#8209;lymphotropic virus (HTLV)</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo has not been studied in patients with HIV&#8209;1,
HIV&#8209;2, HTLV&#8209;1, or HTLV&#8209;2. A negative serology test for HIV is
necessary to ensure acceptance of apheresis material for Zynteglo
manufacturing. Apheresis material from patients with a positive test for HIV
will not be accepted for Zynteglo manufacturing. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Method of administration </span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo is for intravenous use only (see section 6.6
for full details on the administration process).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>After completion of the 4&#8209;day course of
myeloablative conditioning, there must be a minimum of 48&nbsp;hours of washout
before Zynteglo infusion. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Before infusion, it must be confirmed that the
patients identity matches the unique patient information on the Zynteglo
infusion bag(s). The total number of infusion bags to be administered should
also be confirmed with the Lot Information Sheet (see section 4.4).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo infusion should be completed as soon as
possible and no more than 4&nbsp;hours after thawing. Each infusion bag should
be administered in less than 30&nbsp;minutes. In the event that more than one
infusion bag is provided, all infusion bags must be administered. The entire
volume of each infusion bag should be infused. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Standard procedures for patient management after HSC
transplantation should be followed after Zynteglo infusion.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.3 Contraindications</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Hypersensitivity to the active substance or to any of
the excipients listed in section 6.1.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Pregnancy and breast-feeding (see section 4.6).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Previous treatment with HSC gene therapy.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Contraindications to the mobilisation agents and the
myeloablative conditioning agent must be considered.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.4 Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><u><span
style='font-family:"Times New Roman",serif'>Traceability</span></u></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><u><span
style='font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The traceability requirements of cell-based advanced
therapy medicinal products must apply. To ensure traceability the name of the
product, the batch number and the name of the treated patient should be kept
for a period of 30 years.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>General</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Warnings and precautions of the mobilisation agents
and the myeloablative conditioning agent must be considered.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients treated with Zynteglo should not donate
blood, organs, tissues or cells for transplantation at any time in the future.
This information is provided in the Patient Alert Card which must be given to
the patient after treatment. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo is intended solely for autologous use and
must not be administered to other patients. Confirm that the patients identity
matches the unique patient identification information on the Zynteglo infusion
bag(s) and metal cassette(s). Do not infuse Zynteglo if the information on the
patient specific label on the infusion bag(s) or metal cassette(s) do not match
the intended patient.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Risks associated with TDT and iron overload</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Patients with TDT experience iron
overload due to chronic red blood cell (RBC) transfusions that can lead to end
organ damage. HSC transplantation with myeloablative conditioning is not
appropriate for patients with TDT who have evidence of severely elevated iron
in the heart i.e., patients with cardiac T2* &lt;10&nbsp;msec by magnetic
resonance imaging (MRI). MRI of the liver should be performed on all patients
prior to myeloablative conditioning. It is recommended that patients with MRI
results demonstrating liver iron content &#8805;15&nbsp;mg/g undergo liver
biopsy for further evaluation. If the liver biopsy demonstrates bridging
fibrosis, cirrhosis, or active hepatitis, HSC transplantation with
myeloablative conditioning is not appropriate.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Risk of insertional oncogenesis</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>No cases of leukaemia or lymphoma have been reported
in clinical studies with Zynteglo in patients with TDT. There are no reports of
LVV&#8209;mediated insertional mutagenesis resulting in oncogenesis.
Nevertheless, there is a theoretical risk of leukaemia or lymphoma after
treatment with Zynteglo. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients should be monitored annually for leukaemia or
lymphoma (including with a complete blood count) for 15&nbsp;years post
treatment with Zynteglo. If leukaemia or lymphoma is detected in any patient
who received Zynteglo, blood samples should be collected for integration site
analysis. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Serological testing</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>All patients should be tested for HIV-1/2 prior to
mobilisation and apheresis to ensure acceptance of the apheresis material for
Zynteglo manufacturing (see section 4.2). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Interference with serology testing</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>It is important to note that patients who have
received Zynteglo are likely to test positive by polymerase chain reaction
(PCR) assays for HIV due to LVV provirus insertion, resulting in a false
positive test for HIV. Therefore, patients who have received Zynteglo should
not be screened for HIV infection using a PCR-based assay. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Engraftment failure as measured by neutrophil
engraftment</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Treatment with Zynteglo involves the infusion and
engraftment of CD34<sup>+</sup> HSCs that have been genetically modified <i>ex
vivo</i> with a LVV. In clinical trials, no patients failed to engraft bone
marrow, as measured by neutrophil engraftment (N=45). <span style='color:black'>Neutrophil
engraftment occurred on median&nbsp;(min,&nbsp;max) Day&nbsp;21.0 (13, 38)
after medicinal product infusion. </span>Failure of neutrophil engraftment is a
short-term but potentially severe risk, defined as failure to achieve
3&nbsp;consecutive absolute neutrophil counts (ANC) &#8805;500&nbsp;cells/L
obtained on different days by Day&nbsp;43 after infusion of Zynteglo. Patients
who experience neutrophil engraftment failure should receive rescue treatment
with the back-up collection (see section 4.2).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Delayed platelet engraftment</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Platelet engraftment is defined as 3&nbsp;consecutive
platelet values &#8805;20&nbsp;&nbsp;10<sup>9</sup>/L obtained on different
days after Zynteglo infusion, with no platelet transfusions administered for
7&nbsp;days immediately preceding and during the evaluation period.<b><i> </i></b>Patients
with TDT treated with Zynteglo who achieved platelet engraftment had a median
(min, max) platelet engraftment on Day&nbsp;42.0 (19, 191) in clinical trials
(N=45). No correlation was observed between incidence of bleeding and delayed
platelet engraftment. Patients should be made aware of the risk of bleeding
until platelet recovery has been achieved. Patients should be monitored for
thrombocytopenia and bleeding according to standard guidelines. Platelet counts
should be monitored according to medical judgment until platelet engraftment
and platelet recovery are achieved. Blood cell count determination and other
appropriate testing should be promptly considered whenever clinical symptoms
suggestive of bleeding arise. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Anti-retroviral and hydroxyurea use</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients should not take anti&#8209;retroviral
medications or hydroxyurea from at least one month prior to mobilisation until
at least 7&nbsp;days after Zynteglo infusion (see section 4.5). <a
name="_Hlk3111940">If a patient requires anti&#8209;retrovirals for HIV
prophylaxis, Zynteglo treatment, including mobilisation and apheresis of CD34</a></span><sup>+</sup><span
style='font-size:11.0pt'> cells through Zynteglo infusion, should be delayed
until an HIV infection could be adequately ruled out according to local
guidance for HIV testing.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Sodium content</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>This medicinal product contains 391&#8209;1564&nbsp;mg
sodium per dose equivalent to 20 to 78% of the WHO recommended maximum daily
intake of 2&nbsp;g sodium for an adult. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients should not take anti&#8209;retroviral
medicinal products or hydroxyurea from at least one month prior to mobilisation
until at least 7&nbsp;days after Zynteglo infusion (see section 4.4).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Drug-drug interactions between iron chelators and the
myeloablative conditioning agent must be considered. Iron chelators should be
discontinued 7&nbsp;days prior to initiation of conditioning. The Summary of
Product Characteristics (SmPC) for the iron chelator and the myeloablative
conditioning agent must be consulted for the recommendations regarding
co-administration with CYP3A substrates.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Some iron chelators are myelosuppressive. After
Zynteglo infusion, avoid use of these iron chelators for 6&nbsp;months. If iron
chelation is needed, consider administration of non-myelosuppressive iron
chelators (see sections 4.2 and 5.1).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>No formal drug interaction studies have been
performed. Zynteglo is not expected to interact with the hepatic cytochrome P&#8209;450
family of enzymes or drug transporters.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>There is no clinical experience with the use of
erythropoiesis-stimulating agents in patients treated with Zynteglo.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The safety of immunisation with live viral vaccines
during or following Zynteglo treatment has not been studied. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.6 Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Women of childbearing potential/Contraception in males
and females</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt;color:black'>There are insufficient exposure data to
provide a precise recommendation on duration of </span><span style='font-size:
11.0pt'>contraception following treatment with Zynteglo. Women of childbearing
potential and men capable of fathering a child must use a reliable method of
contraception (intra-uterine device or combination of hormonal and barrier
contraception) from start of mobilisation through at least 6&nbsp;months after
administration of Zynteglo. Consult the SmPC of the myeloablative conditioning
agent for information on the need for effective contraception in patients who
undergo conditioning. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Pregnancy</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>A negative serum pregnancy test must be confirmed
prior to the start of mobilisation and re-confirmed prior to conditioning
procedures and before medicinal product administration.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>No clinical data on exposed pregnancies are available.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Reproductive and developmental toxicity studies with
Zynteglo were not performed. Zynteglo must not be used during pregnancy because
of myeloablative conditioning (see section 4.3). It is unknown whether Zynteglo
transduced cells have the potential to be transferred in utero to a foetus.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>There is no opportunity for germline transmission of
the &#946;<sup>A&#8209;T87Q</sup>&#8209;globin gene after treatment with
Zynteglo, therefore the likelihood that an offspring would have general somatic
expression of the &#946;<sup>A&#8209;T87Q</sup>&#8209;globin gene is considered
negligible.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>It is unknown whether Zynteglo is excreted in human
milk. The effect of administration of Zynteglo to mothers on their breast-fed
children has not been studied.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo must not be administered to women who are
breast-feeding.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Fertility</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>There are no data on the effects of Zynteglo on human
fertility. Effects on male and female fertility have not been evaluated in
animal studies. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Data are available on the risk of infertility with
myeloablative conditioning. <span style='color:black'>It is therefore advised
to cryopreserve semen or ova before treatment if possible.</span></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.7 Effects on
ability to drive and use machines</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo has no influence on the ability to drive or
use machines.<br>
<br>
</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The effect of the mobilisation agents and the
myeloablative conditioning agent on the ability to drive or use machines must
be considered.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.8 Undesirable
effects</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Summary of the safety profile</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The safety of Zynteglo was evaluated in
45&nbsp;patients with TDT. The only serious adverse reaction attributed to
Zynteglo was thrombocytopenia (2.2%). <span style='color:black'>Given the small
patient population and size of cohorts, adverse reactions in the table below do
not provide a complete perspective on the nature and frequency of these events.
</span></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Tabulated list of adverse reactions<br>
<br>
</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Adverse reactions are listed by MedDRA body system
organ class and by frequency convention. Frequencies are defined as: very
common <span style='color:#323232'>(&#8805;1/10), and c</span>ommon
(&#8805;1/100 to &lt;1/10). Within each frequency grouping, adverse reactions
are presented in the order of decreasing seriousness.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Tables 1, 2, and 3 are lists of adverse reactions
attributed to mobilisation/apheresis, myeloablative conditioning, and Zynteglo,
respectively, experienced by patients with TDT in clinical trials with Zynteglo.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;
text-autospace:none'><b><span style='font-family:"Times New Roman",serif'>Table
1 Adverse reactions attributed to mobilisation/apheresis</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
  name="_Hlk4086514"><b><span style='font-family:"Times New Roman",serif'>System
  Organ Class (SOC)</span></b></a></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Very Common (&#8805;10%)</span></b></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Common (&#8805;1% - &lt;10%)</span></b></p>
  </td>
 </tr>
 <tr style='height:8.5pt'>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Thrombocytopenia</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Splenomegaly,
  Leukocytosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypocalcaemia</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypokalaemia,
  Hypomagnesaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Psychiatric disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Agitation</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Nervous system
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Headache, Peripheral
  sensory neuropathy</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Dizziness, Head
  discomfort, Paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Cardiac disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Cardiac flutter</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Vascular disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Respiratory, thoracic
  and mediastinal disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypoxia, Epistaxis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Nausea</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Vomiting, Lip
  swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral </span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Skin and subcutaneous
  tissue disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Rash, Hyperhidrosis</span></p>
  </td>
 </tr>
 <tr style='height:22.9pt'>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Musculoskeletal and
  connective tissue disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Bone pain</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Back pain,
  Musculoskeletal discomfort</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>General disorders and
  administration site conditions</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Pyrexia, Influenza
  like illness, Chest discomfort, Chest pain, Injection site reaction, Catheter
  site haemorrhage, Catheter site bruise, Injection site bruising, Fatigue,
  Non-cardiac chest pain, Catheter site pain, Injection site pain, Puncture
  site pain, Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Investigations</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Blood magnesium
  decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Injury, poisoning and
  procedural complications</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Citrate toxicity,
  Contusion, Procedural pain</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always;
page-break-after:avoid;text-autospace:none'><a name="_Hlk4086533"><b><span
style='font-family:"Times New Roman",serif'>Table 2 Adverse
reactions attributed to myeloablative conditioning</span></b></a></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:10.3pt'>
   <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:10.3pt'>
   <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
   style='font-family:"Times New Roman",serif'>SOC</span></b></p>
   </td>
   <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt'>
   <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
   style='font-family:"Times New Roman",serif'>Very Common (&#8805;10%)</span></b></p>
   </td>
   <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt'>
   <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
   style='font-family:"Times New Roman",serif'>Common (&#8805;1% - &lt;10%)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Infections and
  infestations</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Neutropenic sepsis,
  Systemic infection, Staphylococcal infection, Pneumonia, Lower respiratory
  tract infection, Urinary tract infection, Mucosal infection, Cellulitis,
  Vaginal infection, Rash pustular, Folliculitis, Gingivitis, Vulvovaginal
  candidiasis</span></p>
  </td>
 </tr>
 <tr style='height:8.5pt'>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>Blood
  and lymphatic system disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=IT style='font-family:"Times New Roman",serif;color:black'>Febrile
  neutropenia, Neutropenia, Thrombocytopenia, Leukopenia, Anaemia</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>Lymphopenia,
  Leukocytosis, Monocyte count decreased, Neutrophilia, Mean cell haemoglobin
  concentration increased</span></p>
  </td>
 </tr>
 <tr style='height:8.5pt'>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>Endocrine
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=IT style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>Primary
  hypogonadism</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Metabolism and nutrition
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Decreased appetite</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypocalcaemia,
  Hypokalaemia, Metabolic acidosis, Fluid overload, Fluid retention,
  Hypomagnesaemia, Hyponatraemia, Hypophosphataemia, Hyperphosphataemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Psychiatric disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Insomnia</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Anxiety</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Nervous system
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Headache</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Dizziness, Lethargy,
  Dysgeusia, Ageusia, Memory impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Eye disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Conjunctival
  haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Ear and labyrinth
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Vertigo</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Cardiac disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Cardiac failure
  congestive, Atrial fibrillation </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Vascular disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypotension,
  Haematoma, Hot flush</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Respiratory, thoracic
  and mediastinal disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Epistaxis, Pharyngeal
  inflammation</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hypoxia, Pulmonary
  mass, Dyspnoea, Pleural effusion, Rales, Upper-airway cough syndrome, Cough,
  Laryngeal pain, Hiccups, Oropharyngeal pain </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Stomatitis, Vomiting,
  Nausea, Diarrhoea, Gingival bleeding, Constipation, Abdominal pain, Anal
  inflammation </span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Anal haemorrhage,
  Gastritis, Gastrointestinal inflammation, Abdominal distension, Abdominal
  pain upper, Anal fissure, Dyspepsia, Dysphagia, Oesophagitis, Haemorrhoids,
  Proctalgia, Lip dry</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Veno&#8209;occlusive
  liver disease, Alanine aminotransferase increased, Aspartate aminotransferase
  increased, Blood bilirubin increased</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Cholecystitis,
  Cholelithiasis, Hepatomegaly, Jaundice, Transaminases increased,
  Gamma-glutamyltransferase increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Skin and subcutaneous
  tissue disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Alopecia, Pruritus,
  Skin hyperpigmentation</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Petechiae,
  Ecchymosis, Pain of skin, Palpable purpura, Pigmentation disorder, Pruritus
  generalised, Purpura, Sweat gland disorder, Urticaria, Dry skin, Rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Musculoskeletal and
  connective tissue disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Bone pain, Myalgia,
  Pain&nbsp;in&nbsp;extremity, Back pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Renal and urinary
  disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Haematuria,
  Pollakiuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Reproductive system
  and breast disorders</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Vaginal haemorrhage</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Ovarian failure,
  Menstruation irregular, Premature menopause, Blood follicle stimulating
  hormone increased, Blood testosterone decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>General disorders and
  administration site conditions</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Pyrexia, Fatigue,
  Mucosal inflammation</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Face oedema,
  Hypothermia, Feeling cold, Pain, Xerosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>Investigations</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>C&#8209;reactive
  protein increased, Aspergillus test positive, Blood potassium decreased,
  Weight decreased, Blood alkaline phosphatase decreased, Blood magnesium
  decreased, Forced expiratory flow decreased, Protein total decreased, Blood
  albumin decreased, Reticulocyte count decreased, Reticulocyte percentage
  decreased</span></p>
  </td>
 </tr>
 <tr style='height:23.8pt'>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.8pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Injury, poisoning and
  procedural complications</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.8pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.8pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Transfusion reaction,
  Skin abrasion</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;
text-autospace:none'><b><span style='font-family:"Times New Roman",serif'>Table
3 Adverse reactions attributed to Zynteglo</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=602
 style='width:451.75pt;border-collapse:collapse;border:none'>
 <tr style='height:14.35pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>SOC</span></b></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Very Common (&#8805;10%)</span></b></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Common (&#8805;1% - &lt;10%)</span></b></p>
  </td>
 </tr>
 <tr style='height:9.4pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Thrombocytopenia, </span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Leukopenia,
  Neutropenia</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Vascular disorders</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Hot flush</span></p>
  </td>
 </tr>
 <tr style='height:14.05pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.05pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Respiratory, thoracic
  and mediastinal disorders</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.05pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.05pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Dyspnoea</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Abdominal pain</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Musculoskeletal and
  connective tissue disorders</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Pain in extremity</span></p>
  </td>
 </tr>
 <tr style='height:28.5pt'>
  <td width=201 valign=top style='width:150.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>General disorders and
  administration site conditions</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=201 valign=top style='width:150.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.5pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;color:black'>Non-cardiac chest
  pain</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Description of selected adverse reactions</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk4059620"><i><span
style='font-size:11.0pt'>Bleeding</span></i></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Bleeding is a potential complication of
thrombocytopenia subsequent to myeloablative conditioning and treatment with
Zynteglo. The majority of all reported bleeding events were nonserious. A risk
of bleeding exists before platelet engraftment and may continue after platelet
engraftment in patients who have continued thrombocytopenia. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Following platelet engraftment, all patients
maintained platelet levels of &#8805;20&nbsp;&nbsp;10<sup>9</sup>/L. Median
(min, max) times to unsupported platelet counts of &#8805;50&nbsp;&nbsp;10<sup>9</sup>/L
and &#8805;100&nbsp;&nbsp;10<sup>9</sup>/L were 51 (20, 268) days (N=45) and
63.5 (20, 1231) days (N=42), respectively (see section 4.4 for guidance on
platelet monitoring and management).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Hepatic veno-occlusive disease</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Serious events of hepatic VOD occurred in 11.1% of
patients following myeloablative conditioning; 80% of these patients did not
receive prophylaxis for VOD. All patients who experienced VOD received
treatment with defibrotide and recovered. Patients with TDT may be at an
increased risk of VOD following myeloablative conditioning compared with other
patient populations. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><i><span
style='font-size:11.0pt'>Infusion related reactions to Zynteglo</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><span
style='font-size:11.0pt'>Pre-medication for infusion reactions was managed at
physician discretion. Infusion related reactions to Zynteglo were observed in
13.3% of patients and occurred on the day of Zynteglo infusion. All reactions
resolved and the majority were mild. Events included abdominal pain, dyspnoea,
hot flush, and non&#8209;cardiac chest pain in 11.1%, 2.2%, 2.2%, and 2.2% of
patients, respectively. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Paediatric population</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk3021378"></a><a
name="_Hlk2980904"><span style='font-size:11.0pt'>According to available data,
the frequency, type, and severity of adverse reactions in adolescents 12&#8209;17&nbsp;years
of age are similar to adults with the exception that VOD and pyrexia occurred
more frequently in adolescents.</span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Reporting of suspected adverse reactions</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:lightgrey'>the national reporting system listed in <span
class=MsoHyperlink>Appendix V</span>.</span></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.9 Overdose</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>No data from clinical studies are available regarding
overdose of Zynteglo. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5.1 Pharmacodynamic
properties</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Pharmacotherapeutic group: Other haematological
agents, ATC code: B06AX02</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Mechanism of action</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo adds functional copies of a modified
&#946;-globin gene into the patients HSCs through transduction of autologous
CD34<sup>+</sup> cells with BB305 LVV, thereby addressing the underlying
genetic cause of the disease. After Zynteglo infusion, transduced CD34<sup>+</sup>
HSCs engraft in the bone marrow and differentiate to produce RBCs containing
biologically active <span style='color:black'>&#946;<sup>A&#8209;T87Q</sup>&#8209;globin
(a modified &#946;&#8209;globin protein) that will combine with &#945;-globin
to produce functional Hb containing </span>&#946;<sup>A&#8209;T87Q</sup>&#8209;globin
(Hb<span style='color:black'>A<sup>T87Q</sup>). </span>&#946;<sup>A&#8209;T87Q</sup>&#8209;globin
can be quantified relative to other globin species in peripheral blood using
high performance liquid chromatography.<span style='color:black'> </span>&#946;<sup>A&#8209;T87Q</sup>&#8209;globin
expression is designed to correct the &#946;/&#945;&#8209;globin imbalance in
erythroid cells of patients with TDT and has the potential to increase total Hb
to normal levels and eliminate dependence on chronic RBC transfusions. <a
name="_Hlk2981031">Following successful engraftment and achievement of
transfusion independence, the effects of the product are expected to be life&#8209;long.</a></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Pharmacodynamic effects </span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>All patients with TDT with a non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>&nbsp;genotype
who received Zynteglo with at least 3&nbsp;months of follow-up produced HbA<sup>T87Q</sup>
(N=10, HGB&#8209;204; N=4, HGB&#8209;205; N=15, HGB&#8209;207; N=3, HGB&#8209;212).
For patients with at least 6&nbsp;months of follow-up, HbA<sup>T87Q</sup>
generally increased steadily after Zynteglo infusion and stabilised by
approximately Month&nbsp;6. Patients had a Month&nbsp;6 median&nbsp;(min, max)
HbA<sup>T87Q</sup> of 4.901&nbsp;(1.03,&nbsp;9.59)&nbsp;g/dL in the Phase 1/2
studies (N=14, HGB&#8209;204 and HGB&#8209;205) and 9.409&nbsp;(3.35,&nbsp;10.60)&nbsp;g/dL
in ongoing Phase 3 studies (N=16, HGB&#8209;207 and HGB-212). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>HbA<sup>T87Q</sup> remained generally stable through
Month&nbsp;24 with a&nbsp;median (min, max) of
6.444&nbsp;(1.10,&nbsp;10.13)&nbsp;g/dL in the completed Phase 1/2 studies (N=14,
HGB&#8209;204 and HGB&#8209;205) and 8.766&nbsp;(0.89,&nbsp;11.40)&nbsp;g/dL in
the ongoing Phase 3 studies (N=3, HGB&#8209;207). HbA<sup>T87Q</sup> continued
to be stable at last follow-up through Month&nbsp;60, demonstrating stable
integration of the &#946;<sup>A&#8209;T87Q</sup>&#8209;globin gene into long&#8209;term
HSCs and stable expression of the &#946;<sup>A&#8209;T87Q</sup>&#8209;globin
gene in cells of the erythroid lineage. <a name=IDX></a></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><i><span style='font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><a
name="_Hlk535595211"><u><span style='font-size:11.0pt'>Clinical efficacy </span></u></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Efficacy was based on 32&nbsp;adult and adolescent
patients with TDT and a non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype treated with Zynteglo (N=10, HGB&#8209;204; N=4, HGB&#8209;205; N=15,
HGB&#8209;207; N=3, HGB&#8209;212) (see Table 4). <a name="_Hlk2977601">A few
patients have been included in the clinical studies with genotypes
characterised by low endogenous &#946;&#8209;globin production phenotypically
similar to patients with a &#946;<sup>0</sup>/&#946;<sup>0</sup> genotype, such
as patients homozygous for IVS&#8209;I&#8209;110 or IVS&#8209;I&#8209;5. </a></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal'><b><span
style='font-size:11.0pt'>Table 4 Baseline characteristics for non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
patients with TDT &#8805;12 years of age treated with Zynteglo (Studies HGB&#8209;204,
HGB&#8209;205, HGB&#8209;207, HGB&#8209;212, LTF&#8209;303) </span></b></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal'><b><span
style='font-size:11.0pt'>&nbsp;</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:48.6pt'>
  <td width=83 valign=top style='width:62.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=C-BodyText style='margin:0in;line-height:normal'><b><span
  style='font-size:11.0pt'>Study</span></b></p>
  </td>
  <td width=102 valign=top style='width:76.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span lang=EN-GB style='font-size:11.0pt'>Total number
  of patients </span></b></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>(young adults/ adolescents)</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=90 valign=top style='width:67.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>Age</span></b></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(years)</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>median (min, max)</span></p>
  </td>
  <td width=162 valign=top style='width:121.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>Pre-enrolment
  transfusion volumes</span></b></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(mL/kg/year)</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>median (min, max)</span></p>
  </td>
  <td width=167 valign=top style='width:125.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>Pre-enrolment
  transfusion frequency</span></b></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(number/year)</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>median (min, max)</span></p>
  </td>
 </tr>
 <tr style='height:11.9pt'>
  <td width=83 valign=top style='width:62.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=C-BodyText style='margin:0in;line-height:normal'><span
  style='font-size:11.0pt'>HGB&#8209;205</span></p>
  </td>
  <td width=102 valign=top style='width:76.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>4</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(2)</span></p>
  </td>
  <td width=90 valign=top style='width:67.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>young
  adults/ adolescents*</span></p>
  </td>
  <td width=162 valign=top style='width:121.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>181.85</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(138.8,
  197.3)</span></p>
  </td>
  <td width=167 valign=top style='width:125.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>12.50</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(10.5,
  13.0) </span></p>
  </td>
 </tr>
 <tr style='height:11.9pt'>
  <td width=83 valign=top style='width:62.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=C-BodyText style='margin:0in;line-height:normal'><span
  style='font-size:11.0pt'>HGB&#8209;204</span></p>
  </td>
  <td width=102 valign=top style='width:76.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>10</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(2)</span></p>
  </td>
  <td width=90 valign=top style='width:67.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>19.5</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(16, 34)</span></p>
  </td>
  <td width=162 valign=top style='width:121.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>151.28</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(140.0, 234.5)</span></p>
  </td>
  <td width=167 valign=top style='width:125.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>13.75</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(10.0, 16.5)</span></p>
  </td>
 </tr>
 <tr style='height:11.9pt'>
  <td width=83 valign=top style='width:62.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=C-BodyText style='margin:0in;line-height:normal'><span
  style='font-size:11.0pt'>HGB&#8209;207</span></p>
  </td>
  <td width=102 valign=top style='width:76.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>15</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(6)</span></p>
  </td>
  <td width=90 valign=top style='width:67.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>20.0</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(12, 34)</span></p>
  </td>
  <td width=162 valign=top style='width:121.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>192.92</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(152.3, 251.3)</span></p>
  </td>
  <td width=167 valign=top style='width:125.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>17.50</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(11.5, 37.0)</span></p>
  </td>
 </tr>
 <tr style='height:12.3pt'>
  <td width=83 valign=top style='width:62.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=C-BodyText style='margin:0in;line-height:normal'><span
  style='font-size:11.0pt'>HGB&#8209;212</span></p>
  </td>
  <td width=102 valign=top style='width:76.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>3</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(1)</span></p>
  </td>
  <td width=90 valign=top style='width:67.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span lang=PT>adults/ adolescents*</span></p>
  </td>
  <td width=162 valign=top style='width:121.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>175.51</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(170.7, 209.6)</span></p>
  </td>
  <td width=167 valign=top style='width:125.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>21.50</span></p>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>(17.5, 39.5)</span></p>
  </td>
 </tr>
</table>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>*Age range is not provided to protect patient identity.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Transfusion&#8209;dependent &#946;&#8209;thalassaemia
(TDT)</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk2977740"><span
style='font-size:11.0pt'>&nbsp;</span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Patients were considered to be transfusion&#8209;dependent
if they had a history of transfusions of at least 100&nbsp;mL/kg/year of RBCs
or with &#8805;8&nbsp;transfusions of RBCs per year in the 2&nbsp;years
preceding enrolment. In the clinical studies, patients received a median (min,
max) RBC transfusion volume of 175.74&nbsp;(138.8,&nbsp;251.3)&nbsp;mL/kg/year
and a median (min, max) number of 14.75&nbsp;(10.0,&nbsp;39.5)&nbsp;RBC
transfusions per year. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Adolescents were excluded from Phase&nbsp;3 studies if
they had a known and available HLA&#8209;matched related HSC donor. The median
(min, max) age in the studies was 19.0&nbsp;(12,&nbsp;34) years, 56.3% were
females, 59.4% were Asian, and 40.6% White/Caucasian. All patients had a
Karnofsky/Lansky performance score &#8805;80 and the majority (18/32, 56.3%)
had a performance score of 100 at baseline. Cardiac T2* at baseline was &gt;20
msec. The median (min, max) serum ferritin at baseline was 3778.7&nbsp;(784,&nbsp;22517)
pmol/L and median (min, max) liver iron concentration was 6.75&nbsp;(1.0,&nbsp;41.0)&nbsp;mg/g
(N=10, HGB&#8209;204; N=4, HGB&#8209;205; N=15, HGB&#8209;207; N=3, HGB&#8209;212).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Mobilisation and apheresis</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk433984"><span
style='font-size:11.0pt'>&nbsp;</span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>All patients were administered G&#8209;CSF and
plerixafor to mobilise stem cells prior to the apheresis procedure. The planned
dose of G&#8209;CSF was 10&nbsp;g/kg/day in patients with a spleen, and 5&nbsp;g/kg/day
in patients without a spleen, given on Days&nbsp;1 through&nbsp;5 of
mobilisation in the morning. The planned dose of plerixafor was
0.24&nbsp;mg/kg/day, given on Days&nbsp;4 and&nbsp;5 of mobilisation in the
evening. If a third day of collection was needed, plerixafor and G&#8209;CSF
dosing was extended to Day&nbsp;6. The dose of G&#8209;CSF was decreased by
half if white blood cell (WBC) count was &gt;100&nbsp;&nbsp;10<sup>9</sup>/L
prior to the day of apheresis. For most patients, the minimum number of CD34<sup>+</sup>
cells to manufacture Zynteglo was collected with 1&nbsp;cycle of mobilisation
and apheresis. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><i><span
style='font-size:11.0pt'>Pre-treatment conditioning</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><span
style='font-size:11.0pt'>All patients received full myeloablative conditioning
with busulfan prior to treatment with Zynteglo. The planned dose of busulfan
was 3.2&nbsp;mg/kg/day for patients &#8805;18&nbsp;years as a 3&#8209;hour IV
infusion daily for 4&nbsp;days with a recommended target AUC<sub>0-24h </sub>of
3800&#8209;4500&nbsp;M*min. The planned dose of busulfan was 0.8&nbsp;mg/kg
for patients 12&#8209;17&nbsp;years of age as a 2&#8209;hour IV infusion every
6&nbsp;hours for a total of 16&nbsp;doses with a recommended target of AUC<sub>0-6h
</sub>of 950&#8209;1125&nbsp;M*min. The busulfan SmPC was used for information
on appropriate method for determination of patient weight&#8209;based dosing. <a
name="_Hlk2978225">Busulfan dose adjustments were made as needed based on
pharmacokinetic monitoring.</a></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The median (min, max) busulfan dose was 3.50&nbsp;(2.5,&nbsp;5.0)
mg/kg/day (N=32). AUC<sub>0-24h</sub> was measured during Day&nbsp;1 and
informed the dose for Day&nbsp;3; the median (min, max) estimated daily AUC was
4394.5&nbsp;(3030,&nbsp;9087) &#956;M*min (N=32). All patients with non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
genotypes received anti-seizure prophylaxis with agents other than phenytoin
prior to initiating busulfan. Phenytoin was not used for anti-seizure
prophylaxis because of its well understood induction of glutathione&#8209;S&#8209;transferase
and cytochrome P450 and resultant increased clearance of busulfan, and because
of the widespread availability of effective anti&#8209;seizure medications that
do not affect busulfan metabolism.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>In HGB&#8209;207 and HGB&#8209;212 prophylaxis for
VOD/hepatic sinusoidal obstruction syndrome was required per institutional
practice with ursodeoxycholic acid or defibrotide. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Zynteglo administration</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>All patients were administered Zynteglo with a median
(min, max) dose of 7.80&nbsp;&nbsp;10<sup>6 </sup>(5.0,&nbsp;19.4)&nbsp;CD34<sup>+</sup>&nbsp;cells/kg
as an intravenous infusion (N=32).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk956286"></a><a
name="_Hlk955665"><i><span style='font-size:11.0pt'>After Zynteglo
administration</span></i></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>A total of 31.1% of patients (14/45; HGB&#8209;204,
HGB&#8209;205, HGB&#8209;207, HGB&#8209;212) received G&#8209;CSF within
21&nbsp;days after Zynteglo infusion</span><span style='font-size:11.0pt'>.
However, G&#8209;CSF use was not recommended for 21&nbsp;days after Zynteglo
infusion in Phase&nbsp;3 studies.</span><span style='font-size:11.0pt'> </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Studies HGB&#8209;204 and HGB&#8209;205</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>HGB&#8209;204 and HGB&#8209;205 were Phase&nbsp;1/2
open-label, single-arm 24&#8209;month studies that included 22&nbsp;patients
with TDT treated with Zynteglo (N=18, HGB&#8209;204; N=4, HGB&#8209;205), of
whom 14 had a non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup> genotype (N=10,
HGB&#8209;204; N=4, HGB&#8209;205) and 8 had a &#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype in HGB&#8209;204. All patients completed HGB&#8209;204 and HGB&#8209;205
and enrolled for long&#8209;term follow&#8209;up in the LTF&#8209;303 study.
The median (min, max) duration of follow-up of patients with a non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype was 44.63&nbsp;(35.8,&nbsp;61.3)<span class=MsoFootnoteReference> </span>months.
<a name="_Hlk4078994">All patients remain alive at last follow-up. </a></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The primary endpoint was transfusion independence (TI)
by Month&nbsp;24, defined as a weighted average Hb&nbsp;&#8805;9&nbsp;g/dL
without any RBC transfusions for a continuous period of &#8805;12&nbsp;months
at any time during the study after infusion of Zynteglo. Of the patients with a
non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup> genotype, 11/14&nbsp;(78.6%,&nbsp;95%
CI 49.2%&#8209;95.3%) achieved TI by Month&nbsp;24 (Table 5). Among these
11&nbsp;patients, the median (min, max) weighted average Hb during TI was 10.51&nbsp;(9.3,&nbsp;13.3)&nbsp;g/dL
(Table 5). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>All patients who have achieved TI at any time have
maintained TI at Month&nbsp;36 with a min, max duration of TI of 28.3+,&nbsp;57.6+&nbsp;months
(N=11). The median (min, max) time to last RBC transfusion was
0.46&nbsp;(0.2,&nbsp;5.8)<span class=MsoFootnoteReference> </span>months
following Zynteglo infusion. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>In the 3 patients who did not achieve TI, reductions
of 100%, 86.9% and 26.8% in transfusion volume requirements and of 100%, 85.3%
and 20.7% in transfusion frequency were observed between Month&nbsp;6 through
Month&nbsp;24 visit when compared to their pre-study levels of RBC
transfusions. Reductions in volume and frequency were maintained at last follow&#8209;up
in LTF&#8209;303.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The median (min, max) total Hb at Month&nbsp;6 for
patients who had not received a transfusion for the prior 60&nbsp;days was
10.60&nbsp;(7.6,&nbsp;13.4)&nbsp;g/dL (N=11). Total Hb remained stable at
Month&nbsp;24 with a median (min, max) of 10.60&nbsp;(8.8,&nbsp;13.7)&nbsp;g/dL
(N=12) and at Month&nbsp;36 with a median (min, max) of
10.60&nbsp;(7.8,&nbsp;13.5)&nbsp;g/dL (N=13).&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>After Zynteglo
infusion, patient iron chelation was managed at physician discretion. Of the
14&nbsp;non&#8209;&#946;<sup>0/</sup>&#946;<sup>0</sup> patients treated in HGB&#8209;204
and HGB&#8209;205 that completed Month&nbsp;6, 9&nbsp;patients (64.3%) reported
ongoing chelation use at last follow-up. The remaining 5&nbsp;patients (35.7%)
had stopped iron chelation, of whom 4&nbsp;patients (28.6%) have stopped
chelation for at least 6&nbsp;months with median (min, max) time from stopping
chelation to last follow-up of 26.40&nbsp;(11.5, 42.2) months for these
4&nbsp;patients. Additionally, of the 14&nbsp;treated patients, 3&nbsp;patients
in HGB&#8209;205 (21.4%) received phlebotomy to remove iron. For the
11&nbsp;patients that achieved TI, 4 patients (36.4%) stopped chelation for at
least 6&nbsp;months and 3&nbsp;patients (27.3%) received phlebotomy.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk4398701"><span
style='font-size:11.0pt'>At 48&nbsp;months after infusion of Zynteglo for
patients who achieved TI, the median reduction (min, max) in serum ferritin
levels from baseline was 70.00%&nbsp;(39.2,&nbsp;84.8) (N=5, HGB&#8209;204;
N=2, HGB&#8209;205). The median reduction in liver iron content from baseline
was 62.50%, ranging from an 83.3% reduction to a 269.2% increase (N=5, HGB&#8209;204;
N=2, HGB&#8209;205).</span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Studies HGB&#8209;207 and HGB&#8209;212</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Hlk774161"><span
style='font-size:11.0pt'>HGB&#8209;207 and HGB&#8209;212 are ongoing
Phase&nbsp;3 open&#8209;label, single-arm 24&#8209;month studies that are
planned to include approximately 39&nbsp;adults, adolescents, and children with
TDT (N=23, HGB&#8209;207; N=16,&nbsp;HGB&#8209;212), of whom 29 have a non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype (N=23, HGB&#8209;207; N=6, HGB&#8209;212) and 10&nbsp;have a &#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype in HGB&#8209;212. </span></a><span style='font-size:11.0pt'>These
studies are conducted with improved transduction compared to Phase&nbsp;1/2
studies, resulting in increased average number of functional copies of the
transgene (&#946;<sup>A&#8209;T87Q</sup>&#8209;globin) integrated in the
autologous CD34<sup>+</sup> cells. <a name="_Hlk4244937">Eighteen adults and
adolescents with TDT with a non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
genotype have been treated with Zynteglo in Phase 3 studies (N=15,&nbsp;HGB&#8209;207;&nbsp;N=3,&nbsp;HGB&#8209;212)
and their median (min, max) duration of follow-up was
15.92&nbsp;(5.6,&nbsp;26.3)&nbsp;months.</a> <a name="_Hlk4079020">All patients
remain alive at last follow&#8209;up.</a></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The primary endpoint was transfusion independence (TI)
by Month&nbsp;24, defined as a weighted average Hb &#8805;9&nbsp;g/dL without
any RBC transfusions for a continuous period of &#8805;12&nbsp;months at any
time during the study after infusion of Zynteglo. Ten patients are evaluable
for assessment of TI. Of these, 9/10&nbsp;(90.0%, 95%&nbsp;CI&nbsp;55.5&#8209;99.7%)
achieved TI at last follow&#8209;up. Among these 9&nbsp;patients, the median
(min, max) weighted average Hb during TI was 12.22&nbsp;(11.4,&nbsp;12.8)&nbsp;g/dL
(Table 5). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>All patients who have achieved TI have maintained TI
with a min, max duration of TI of 12.1+,&nbsp;21.3+&nbsp;months (N=9). The
median (min, max) time to last RBC transfusion was
1.08&nbsp;(0.5,&nbsp;2.2)&nbsp;months following Zynteglo infusion. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a
name="_Hlk517114053"><span style='font-size:11.0pt'>For the only patient who
did not achieve TI, a reduction of 51.5% in transfusion volume requirements and
a reduction of 43.4% in transfusion frequency were observed from Month 12 to
Month 24 when compared to their pre-study levels of RBC transfusions. </span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The median (min, max) total Hb at Month&nbsp;6 for
patients who had not received a transfusion for the prior 60 days was 11.85&nbsp;(8.4,&nbsp;13.3)&nbsp;g/dL
(N=18). Total Hb remained stable at Month&nbsp;24 with a median (min, max) of
12.85&nbsp;(12.5,&nbsp;13.2)&nbsp;g/dL (N=2).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a
name="_Hlk536092762"><span style='font-size:11.0pt'>After Zynteglo infusion,
patient iron chelation was managed at physician discretion. Of the 18&nbsp;non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup>
patients treated in HGB&#8209;207 and HGB&#8209;212 that completed
Month&nbsp;6, 5&nbsp;patients (27.8%) reported ongoing chelation use at last
follow-up. The remaining 13&nbsp;patients (72.2%) had stopped iron chelation,
of whom 9&nbsp;patients (50.0%) have stopped chelation for at least
6&nbsp;months with median (min, max) time from stopping chelation to last
follow-up of 16.89&nbsp;(6.9,&nbsp;25.4)&nbsp;months for these 9&nbsp;patients.
Additionally, of the 18&nbsp;treated patients, 5&nbsp;patients in HGB&#8209;207
(27.8%) received phlebotomy to remove iron. For the 9&nbsp;patients that
achieved TI, 6&nbsp;patients (66.7%) stopped chelation for at least
6&nbsp;months and 2&nbsp;patients (22.2%) received phlebotomy.</span></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal'></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Exploratory analyses were performed to evaluate
resolution of dyserythropoiesis, the fundamental pathophysiological
characteristic of TDT, in the bone marrow. Bone marrow biopsies taken before
treatment were consistent with a diagnosis of TDT, including a low
myeloid/erythroid ratio (N=15, HGB&#8209;207; N=3, HGB&#8209;212), reflective
of erythroid hyperplasia. For 9&nbsp;patients who achieved TI and had a
Month&nbsp;12 bone marrow assessment, myeloid/erythroid ratios increased from a
median (min, max) of 0.2&nbsp;(0.1&nbsp;to 0.7) at baseline to a median (min,
max) of 0.83&nbsp;(0.6 to 1.9) at Month 12&nbsp;after Zynteglo infusion,
suggesting that Zynteglo improves erythropoiesis in patients with TDT. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><a name="_Ref442134"><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></a></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><u><span
style='font-size:11.0pt'>Overall results</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCaption style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;line-height:normal'><span style='font-size:11.0pt'>Figure&nbsp;</span><span
style='font-size:11.0pt'>1 Median total haemoglobin over time in
non-&#946;<sup>0</sup>/&#946;<sup>0</sup> TDT patients treated with Zynteglo
who have achieved transfusion independence (Studies HGB&#8209;204, HGB&#8209;205,
HGB&#8209;207, LTF&#8209;303)</span></p>

<p class=Default style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB><img width=576 height=336 id="Picture 3"
src="Zynteglo_clean_files/image002.jpg"></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><i><span style='font-family:"Times New Roman",serif'>Bars represent
interquartile ranges.</span></i></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><a name="_Hlk31017224"><i><span style='font-family:"Times New Roman",serif'>Total
Hb represents those without any acute or chronic RBC transfusions within 60
days prior to the measurement date.</span></i></a></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
name="_Hlk4231781"><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></a></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always'><b><span
style='font-family:"Times New Roman",serif'>Table 5 Efficacy
outcomes for non&#8209;&#946;<sup>0</sup>/&#946;<sup>0</sup> TDT patients
treated with Zynteglo (Studies HGB&#8209;204, HGB&#8209;205, HGB&#8209;207, HGB&#8209;212,
LTF&#8209;303)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;text-indent:-1.0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=591
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:71.3pt'>
   <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif'>HbA<sup>T87Q</sup>
   at 6&nbsp;months</span></b></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>n</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>median
   (min, max)</span></p>
   </td>
   <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif'>HbA<sup>T87Q
   </sup>at 24 months</span></b></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>n</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>median</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(min,
   max)</span></p>
   </td>
   <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Hb
   at 6&nbsp;months*</span></b></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>n</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>median</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(min,
   max)</span></p>
   </td>
   <td width=87 valign=top style='width:65.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Hb
   at 24&nbsp;months*</span></b></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>(g/dL)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>n</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>median</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(min,
   max)</span></p>
   </td>
   <td width=72 valign=top style='width:.75in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span lang=FR style='font-family:"Times New Roman",serif'>TI**</span></b></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span lang=FR style='font-family:"Times New Roman",serif'>n/N^
   </span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span lang=FR style='font-family:"Times New Roman",serif'>(%)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal;text-autospace:none'><span lang=FR style='font-family:
   "Times New Roman",serif'>[95% CI]</span></p>
   </td>
   <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span lang=DA style='font-family:"Times New Roman",serif'>WA
   Hb during TI </span></b><span lang=DA style='font-family:"Times New Roman",serif'>(g/dL)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>n</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>median</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(min,
   max)</span></p>
   </td>
   <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Duration
   of TI</span></b></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>(months)</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>n</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>median</span></p>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><span style='font-family:"Times New Roman",serif'>(min,
   max)</span></p>
   </td>
  </tr>
 </thead>
 <tr style='height:2.35pt'>
  <td width=591 colspan=7 valign=top style='width:443.5pt;border:solid windowtext 1.0pt;
  border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:2.35pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>HGB-205</span></p>
  </td>
 </tr>
 <tr style='height:37.55pt'>
  <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>4</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>7.543</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(4.94,
  9.59)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>4</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>8.147</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(6.72,
  10.13)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>4</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10.73</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(7.6,
  13.4)</span></p>
  </td>
  <td width=87 valign=top style='width:65.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>4</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10.91</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(8.8,
  13.6)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>3/4 </span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(75.0%)<br>
  [19.4, 99.4]</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>3</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>11.35</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(10.5,
  13.0)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.55pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>3</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>NR </span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(38.2+,
  57.6+)</span></p>
  </td>
 </tr>
 <tr style='height:1.85pt'>
  <td width=591 colspan=7 valign=top style='width:443.5pt;border:solid windowtext 1.0pt;
  border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:1.85pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>HGB-204</span></p>
  </td>
 </tr>
 <tr style='height:37.4pt'>
  <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>4.153</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(1.03,
  8.52)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>5.418</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(1.10,
  9.60)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>7</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>9.20</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(7.7,
  13.3)</span></p>
  </td>
  <td width=87 valign=top style='width:65.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>8</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10.35</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(9.1,
  13.7)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>8/10
  (80.0%)</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>[44.4,
  97.5]</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>8</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10.27</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(9.3,
  13.3)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>8</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>NR </span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(28.3+,
  51.3+)</span></p>
  </td>
 </tr>
 <tr style='height:5.3pt'>
  <td width=591 colspan=7 valign=top style='width:443.5pt;border:solid windowtext 1.0pt;
  border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:5.3pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>HGB-207</span></p>
  </td>
 </tr>
 <tr style='height:37.4pt'>
  <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>13</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>9.324</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(3.35,
  10.60)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>3</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>8.766</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(0.89,
  11.40)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>15</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>11.80</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(8.4,
  13.3)</span></p>
  </td>
  <td width=87 valign=top style='width:65.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>2</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>12.85</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(12.5,
  13.2)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>9/10</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(90.0%)<br>
  [55.5, 99.7]</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>9</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>12.22</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>(11.4,
  12.8)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>9</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>NR</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(12.1+,
  21.3+)</span></p>
  </td>
 </tr>
 <tr style='height:.2in'>
  <td width=591 colspan=7 style='width:443.5pt;border:solid windowtext 1.0pt;
  border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif;color:black'>HGB-212</span></p>
  </td>
 </tr>
 <tr style='height:37.4pt'>
  <td width=86 valign=top style='width:.9in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>3</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>10.094</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(5.06,
  10.33)</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>NA***</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>3</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>12.10</span></p>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>(8.5,
  12.2)</span></p>
  </td>
  <td width=87 valign=top style='width:65.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;text-autospace:none'><span style='font-family:"Times New Roman",serif'>NA***</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>NA***</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>NA***</span></p>
  </td>
  <td width=86 valign=top style='width:.9in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span style='font-family:"Times New Roman",serif'>NA***</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><span style='font-family:"Times New Roman",serif;color:white'>*Patients
who have not received transfusions in the prior 60 days. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><span style='font-family:"Times New Roman",serif'>**Transfusion
independence (TI): a weighted average Hb &#8805;9&nbsp;g/dL without any RBC
transfusions for a continuous period of &#8805;12 months at any time during the
study after medicinal product infusion.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><span style='font-family:"Times New Roman",serif'>***No patients are
currently evaluable for these endpoints. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><span style='font-family:"Times New Roman",serif'>N^ represents the total
number of patients evaluable for TI, defined as patients who have completed
their parent study (i.e., 24 months of follow&#8209;up), or achieved TI, or
will not achieve TI in their parent study. </span></p>

<p class=Default><span style='font-size:11.0pt'>NR = Not reached. NA = Not
applicable. Hb = Total Hb. WA Hb = Weighted average Hb.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Paediatric population</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The European Medicines Agency has deferred the
obligation to submit the results of studies with Zynteglo in one or more subsets
of the paediatric population in &#946;&#8209;thalassaemia (see section 4.2 for
information on paediatric use).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>This medicinal product has been authorised under a
so-called conditional approval scheme. This means that further evidence on
this medicinal product is awaited. The European Medicines Agency will review
new information on this medicinal product at least every year and this SmPC
will be updated as necessary.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo is an autologous gene therapy medicinal
product consisting of autologous cells that have been genetically modified <i>ex
vivo</i>. The nature of Zynteglo is such that conventional studies on
pharmacokinetics, absorption, distribution, metabolism, and elimination are not
applicable.<a name="_Hlk500249629"></a></span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.3 Preclinical
safety data</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Conventional mutagenicity, carcinogenicity and
reproductive and developmental toxicity studies have not been conducted.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The pharmacology, toxicology and genotoxicity of the
BB305 LVV used for transduction in the manufacture of Zynteglo were evaluated <i>in
vitro</i> and <i>in vivo</i>. An <i>in vitro</i> immortalisation (IVIM) assay
conducted with BB305 LVV&#8209;transduced mouse bone marrow cells (BMCs) showed
minimal mutagenic potential (Fitness Score &#8776; 0.1&nbsp;&nbsp;10<sup>-4</sup>).
Insertion site analysis (ISA) of pre-transplantation transduced mouse BMCs and
human CD34<sup>+</sup> HSCs showed no enrichment for insertion in or near
cancer-related genes. A pharmacology, biodistribution, toxicity and
genotoxicity study was conducted in a mouse model of &#946;&#8209;thalassaemia.
In this study, there was no evidence of toxicity, genotoxicity or oncogenesis
(tumorigenicity) related to BB305 LVV integration, and no toxicity related to
production of &#946;<sup>A&#8209;T87Q</sup>&#8209;globin. ISA of
post-transplantation BMCs demonstrated no preferred integration in the
proximity of or within genes associated clinically (for gamma retroviral
vectors) with either clonal dominance or leukaemia, and no evidence of clonal
dominance was observed. Additional studies with human CD34<sup>+</sup> HSCs
administered to immunodeficient, myeloablated mice demonstrated no toxicity,
tumorigenicity or genotoxicity.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.1 List of
excipients</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Cryostor CS5</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Sodium chloride</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>In the absence of compatibility studies, this
medicinal product must not be mixed with other medicinal products.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Frozen: 1 year at &#8804;-140C.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Once thawed: maximum 4&nbsp;hours at room temperature
(20C&#8209;25C).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Store in the vapour phase of liquid nitrogen at
&#8804;-140C until ready for thaw and administration. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Keep the infusion bag(s) in the metal cassette(s). </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Do not re-freeze after thawing.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.5 Nature and
contents of container </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>20&nbsp;mL fluorinated ethylene propylene infusion
bag(s), each packed in a transparent pouch inside a metal cassette. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Zynteglo is shipped from the manufacturing facility to
the infusion centre storage facility in a cryoshipper, which may contain
multiple metal cassettes intended for a single patient. Each metal cassette
contains one infusion bag with Zynteglo. A patient may have multiple infusion
bags. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.6 <a
name="_Hlk31012748">Special precautions for disposal and other handling</a></span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Irradiation could lead to inactivation of the product.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Precautions to be taken before handling or
administering the medicinal product</span></i></p>

<p class=C-BodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span style='font-size:
11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>This medicinal product contains
genetically modified human blood cells. Healthcare professionals handling
Zynteglo should take appropriate precautions (wearing gloves, protective
clothing and eye protection) to avoid potential transmission of infectious
diseases. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Preparation for the infusion</span></i></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;line-height:normal'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt'>Remove each metal cassette from liquid nitrogen
storage and remove each infusion bag from the metal cassette.</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;line-height:normal'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt'>Confirm that Zynteglo is printed on the infusion
bag(s).</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;line-height:normal'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt'>Confirm that patient identity matches the unique
patient identification information located on the Zynteglo infusion bag(s). Do
not infuse Zynteglo if the information on the patient specific&#8209;label on
the infusion bag does not match the intended patient.</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;line-height:normal'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt'>Account for all infusion bags and confirm each
infusion bag is within the expiry date using the accompanying Lot Information
Sheet. </span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;line-height:normal'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt'>Each infusion bag should be inspected for any breaches
of integrity before thawing and infusion. If an infusion bag is compromised,
follow the local guidelines and contact bluebird bio immediately.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><i><span
style='font-size:11.0pt'>Thaw and administration</span></i></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-13.5pt;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Thaw Zynteglo at 37C in a water
bath or dry bath. Thawing of each infusion bag takes approximately 2 to 4&nbsp;minutes.
Do not overthaw the medicinal product. Do not leave the medicinal product
unattended and do not submerge the infusion ports if thawed in a water bath.</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-13.5pt;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>After thaw, mix the medicinal
product gently by massaging the infusion bag until all of the contents are
uniform. Expose the sterile port on the infusion bag by tearing off a
protective wrap covering the port. </span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-13.5pt;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Access the medicinal product
infusion bag and infuse per the administration sites standard procedures for
administration of cell therapy products. Do not use an in-line blood filter or
an infusion pump.</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-13.5pt;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Do not sample, alter, or irradiate
the medicinal product.</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-13.5pt;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Administer each infusion bag of
Zynteglo via intravenous infusion over a period of less than 30&nbsp;minutes.
If more than one infusion bag is provided, administer each infusion bag
completely before proceeding to thaw and infuse the next bag.</span></p>

<p class=C-Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-13.5pt;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Infuse Zynteglo as soon as
possible and no more than 4&nbsp;hours after thawing. Flush all Zynteglo
remaining in the infusion bag and any associated tubing with at least
50&nbsp;mL of 0.9% sodium chloride solution to ensure as many cells as possible
are infused into the patient.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'>Precautions to be taken for the disposal of the
medicinal product</span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><u><span
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The medicinal product contains genetically&#8209;modified
cells. Local guidelines on handling human-derived material should be followed
for unused medicinal products or waste material. All material that has been in
contact with Zynteglo (solid and liquid waste) should be handled and disposed
of as potentially infectious waste in accordance with local guidelines on
handling human-derived material. </span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>bluebird bio (Netherlands) B.V.</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Stadsplateau 7</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>WTC Utrecht</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>3521AZ Utrecht</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The Netherlands</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>8. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>EU/1/19/1367/001</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Date of first authorisation: 29 May
2019</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>10. DATE OF REVISION
OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>{DD month YYYY}</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency </span><a href="http://www.ema.europa.eu"><span
lang=EN-GB style='font-family:"Times New Roman",serif'>http://www.ema.europa.eu</span></a><u><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:blue'> </span></u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&lt;, and on the website
of {name of MS Agency (link)}&gt;. <br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;text-indent:-27.0pt;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;text-indent:-27.0pt;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;text-indent:-27.0pt;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;text-indent:-27.0pt;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>A. MANUFACTURER(S) OF
THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>B. CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>C. OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>D. CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>E. SPECIFIC OBLIGATION
TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING
AUTHORISATION</span></b></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:27.0pt;text-indent:-27.0pt;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A. MANUFACTURER(S) OF THE
BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Name and address of the manufacturer(s) of the
biological active substance(s)</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Minaris
Regenerative Medicine GmbH</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Haidgraben
5</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>85521
Ottobrunn</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>GERMANY</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Name and address of the manufacturer(s) responsible
for batch release</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Minaris
Regenerative Medicine GmbH</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Haidgraben
5</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>85521
Ottobrunn</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>GERMANY</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><a name="OLE_LINK2"><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>B.</span></b></a><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Medicinal
product subject to special and restricted medical prescription (see Annex I:
Summary of Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>C.  OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span style='font-family:"Times New Roman",serif'>Periodic
Safety Update Reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
requirements for submission of PSURs for this medicinal product are set out in
the list of Union reference dates (EURD list) </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>provided for under Article 107c(7)
of Directive 2001/83/EC and any subsequent updates published on the European
medicines web-portal.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
marketing authorisation holder (MAH) shall submit the first PSUR for this
product within 6&nbsp;months following authorisation. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>D. CONDITIONS OR RESTRICTIONS
WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span style='font-family:"Times New Roman",serif'>Risk
management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>The marketing
authorisation holder (MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>An updated RMP should be
submitted:</span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency;</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span style='font-family:"Times New Roman",serif'>Additional
risk minimisation measures </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Prior to launch of
Zynteglo in each Member State the Marketing Authorisation Holder (MAH) must
agree about the content and format of the educational and controlled
distribution programme, including communication media, distribution modalities,
and any other aspects of the programme, with the National Competent Authority. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
educational and controlled distribution programme is aimed at providing
information on the safe use of Zynteglo.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
MAH shall ensure that in each Member State where Zynteglo is marketed, all
healthcare professionals and patients/carers who are expected to prescribe,
dispense and/or use Zynteglo have access to/are provided with the following
educational package to be disseminated through professional bodies:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Physician
educational material</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Patient
information pack</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>The physician
educational material </span></b><span lang=EN-GB style='font-family:"Times New Roman",serif'>should
contain:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
Summary of Product Characteristics </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Guide
for healthcare professionals </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Guide
for handling and method of administration.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
Guide for healthcare professionals</span></b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> shall contain the following key elements:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Warnings
and precautions of the mobilisation agents and the myeloablative conditioning
agent must be considered.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Treatment
with Zynteglo in the clinical trials was associated with delayed platelet
engraftment. No correlation was observed between incidence of bleeding adverse
events (AEs) and time to platelet engraftment. Precautions regarding bleeding
consequences of thrombocytopenia need to be taken. Patients should be made
aware of the risk of bleeding events that are not easily identifiable, such as
internal bleeding. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Treatment
with Zynteglo is in theory associated with the risk of insertional mutagenesis,
potentially leading to development of malignancy. All patients must be advised
on signs of leukaemia and to seek immediate medical attention if these signs
are present.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>A
negative serology test for HIV is necessary to ensure acceptance of apheresis
material for Zynteglo manufacturing.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
potential risk of loss of response to gene therapy may lead to loss of
transfusion independence or increase transfusion needs for patients who did not
reach transfusionindependence.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>All
patients should receive annual monitoring of complete blood counts and total
haemoglobin levels to monitor for leukaemia/lymphoma and maintenance of
efficacy, respectively.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
short-term potential risk of treatment with Zynteglo represents failure of
engraftment, which shall be managed by administration of rescue cells. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
need to explain and to ensure that patients understand:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>potential
risks of treatment with Zynteglo </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>signs
of leukaemia/lymphoma and what action to take</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>content
of patients guide</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>the
need to carry the patient alert card and show it to every healthcare
professional</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>enrolment
in the drug product Registry.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Scope
of the Registry and how to enrol patients.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
Guide to handling and method of administration for healthcare professionals</span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> shall contain the
following key elements:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Instructions
on receiving and storing of Zynteglo and how to check Zynteglo prior to
administration</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Instructions
about the thawing of Zynteglo</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Instructions
on protective equipment and treatment of spills.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
patient information pack</span></b><span lang=EN-GB style='font-family:"Times New Roman",serif'>
should contain:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Package
leaflet</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>A
patient/carer guide</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>A
patient alert card.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
patient/carer</span></b><span lang=EN-GB style='font-family:"Times New Roman",serif'>
<b>guide </b>shall contain the following key messages:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Treatment
with Zynteglo is in theory associated with the risk of development of
malignancy. Signs of leukaemia and the need to obtain urgent medical care if
these signs are present. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Patient
alert card and the need to carry it on their person and tell any treating
healthcare professional that they were treated with Zynteglo.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
potential risk of loss of response to gene therapy may lead to loss of
transfusion independence or increase transfusion needs for patients who did not
reach transfusion-independence.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
importance of annual check-ups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Treatment
with Zynteglo is associated with the risk of delayed platelet engraftment that
could lead to an increased tendency for bleeding. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Signs
and symptoms of bleeding and the need to contact the physician if any signs of
unusual or prolonged bleeding or any other relevant signs are present.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Enrolment
in the drug product Registry.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
patient alert card</span></b><span lang=EN-GB style='font-family:"Times New Roman",serif'>
shall contain the following key messages:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Information
of risk of delayed platelet engraftment, potentially leading to bleeds, and
theoretical risks.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Statement
that the patient was treated with gene therapy and should not donate blood,
organs, tissues, or cells.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Statement
that the patient was treated with Zynteglo, including LOT number and treatment
date(s).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Details
on reporting of adverse effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Information
on the possibility of false positivity of certain commercial HIV tests because
of Zynteglo.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.75in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Contact
details where a health care professional can receive further information.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>The MAH shall ensure
that in each Member State where Zynteglo is marketed, a system aimed to control
distribution to Zynteglo beyond the level of control ensured by routine risk
minimisation measures. The following requirements need to be fulfilled before
the product is prescribed, manufactured, dispensed and used:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-.1pt;margin-bottom:0in;line-height:
     normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Zynteglo
     will only be available through bluebird bio qualified treatment centres to
     ensure traceability of the patient`s cells and manufactured drug product
     between the treating hospital and manufacturing site. The selection of the
     treatment centres will be conducted in collaboration with national health
     authorities as appropriate.</span></li>
</ul>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span style='font-family:"Times New Roman",serif'>Obligation
to conduct post-authorisation measures </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
MAH shall complete, within the stated timeframe, the below measures:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="81%" valign=top style='width:81.28%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Description</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.72%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="81%" valign=top style='width:81.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>In
  order to further confirm the appropriateness of the acceptance criteria, the
  MAH should re-evaluate the acceptance criteria for attributes related to
  potency tests using batch release data and clinical results after 6 months
  follow-up of 20 patients treated with commercial batches. </span></p>
  </td>
  <td width="18%" valign=top style='width:18.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Interim report: at each annual renewal </span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>When 20 patients have been treated with 6 months
  follow-up</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="81%" valign=top style='width:81.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Non interventional post-authorisation safety study
  (PASS): In order to further characterise and contextualise the long-term
  safety and efficacy of Zynteglo in patients 12 years and older with
  transfusion-dependent &#946;&#8209;thalassaemia (TDT) who do not have a
  &#946;<sup>0</sup>/&#946;<sup>0</sup> genotype, the MAH should conduct and
  submit the results of a study based on data from a product registry (REG-501)
  and use data on HLA&#8209;matched allogenic HSCT treated patients from an
  established European registry as a comparator group.</span></p>
  </td>
  <td width="18%" valign=top style='width:18.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Protocol submission: December&nbsp;2020</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Interim results: </span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>- at each annual renewal </span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>- Dec. 2024</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>- Dec. 2034</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Final results: Q4 2039</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>E. SPECIFIC OBLIGATION TO
COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING
AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>This
being a conditional marketing authorisation and pursuant to Article 14(7) of
Regulation (EC) No 726/2004, the MAH shall complete, within the stated
timeframe, the following measures:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="81%" valign=top style='width:81.1%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
   0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB
   style='font-family:"Times New Roman",serif'>Description</span></b></p>
   </td>
   <td width="18%" valign=top style='width:18.9%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
   0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB
   style='font-family:"Times New Roman",serif'>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="81%" valign=top style='width:81.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>In order to confirm the efficacy and safety of
  Zynteglo in patients 12 years and older with transfusion-dependent
  &#946;-thalassaemia (TDT) who do not have a &#946;<sup>0</sup>/&#946;<sup>0 </sup>genotype,
  the MAH should submit interim and final data on Study HGB&#8209;207</span></p>
  </td>
  <td width="18%" valign=top style='width:18.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Interim results: at each annual renewal </span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Final results: December 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="81%" valign=top style='width:81.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>In order to confirm the efficacy and safety of
  Zynteglo in patients 12 years and older with transfusion-dependent &#946;-thalassaemia
  (TDT) who do not have a &#946;<sup>0</sup>/&#946;<sup>0</sup> genotype, the
  MAH should submit interim and final data from patients with a severe
  non-&#946;<sup>0</sup>/&#946;<sup>0</sup> genotype such as IVS-I-110 included
  in Study HGB&#8209;212.</span></p>
  </td>
  <td width="18%" valign=top style='width:18.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Interim results: at each annual renewal </span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Final results: December 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="81%" valign=top style='width:81.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>In order to confirm the efficacy and safety of
  Zynteglo in patients 12 years and older with transfusion-dependent
  &#946;-thalassaemia (TDT) who do not have a &#946;<sup>0</sup>/&#946;<sup>0</sup>
  genotype, the MAH should submit interim data and the 5 years follow-up
  results of Study LTF-303.</span></p>
  </td>
  <td width="18%" valign=top style='width:18.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Interim results: at each annual renewal </span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Final results: December 2024</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>A.
LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;background:white'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING  METAL CASSETTE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Zynteglo 1.2&#8209;20&nbsp;&nbsp;10<sup>6</sup>&nbsp;cells/mL
dispersion for infusion </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(betibeglogene
autotemcel)</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><a name="_Hlk793172"><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.</span></b></a><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>A genetically modified autologous
CD34<sup>+</sup> cell enriched population that contains haematopoietic stem
cells transduced with lentiviral vector encoding the &#946;<sup>A-T87Q</sup>-globin
gene with a strength of 1.2&#8209;20&nbsp;&nbsp;10<sup>6</sup> cell/mL. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;vertical-align:
baseline'><span style='font-family:"Times New Roman",serif'>Also contains
Cryostor CS5 and sodium chloride.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;vertical-align:
baseline'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;background:lightgrey'>Dispersion
for infusion</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>20&nbsp;mL</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>See Lot Information Sheet for
number of infusion bags and CD34<sup>+</sup> cells per kg for this patient.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Read the package leaflet
before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>For intravenous use.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>For autologous use only.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>EXP:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Store in the vapour
phase of liquid nitrogen at &#8804;-140C until ready for thaw and
administration. Keep infusion bag(s) in the metal cassette(s). Once thawed do
not re-freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>This medicine contains
genetically&#8209;modified cells. Unused medicine must be disposed of in
compliance with the local guidelines on handling human-derived material. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>bluebird bio (Netherlands) B.V.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Stadsplateau 7</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>WTC Utrecht</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>3521AZ Utrecht</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>The Netherlands</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=PT
style='font-family:"Times New Roman",serif'>Tel: +31 (0) 303 100 450</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=PT
style='font-family:"Times New Roman",serif'>e-mail: medinfo@bluebirdbio.com</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=PT
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=PT
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>EU/1/19/1367/001</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> BATCH NUMBER,
DONATION AND PRODUCT CODES</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Patient ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>COI ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Last Name:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>First Name: </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Date of Birth:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>DIN:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Lot: </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Bag ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black;background:
#CCCCCC'>Justification for not including Braille accepted.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black;background:
#CCCCCC'>Not applicable.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black;background:
lightgrey'>Not applicable.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>INFUSION
BAG </span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Zynteglo 1.2&#8209;20&nbsp;&nbsp;10<sup>6</sup>&nbsp;cells/mL
dispersion for infusion </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(betibeglogene
autotemcel)</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>For intravenous use.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Read the package leaflet
before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>EXP:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> BATCH NUMBER,
DONATION AND PRODUCT CODES</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Patient ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>COI ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Last Name </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>First Name:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Date of Birth:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>DIN:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Lot: </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Bag ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>See Lot Information Sheet for
number of infusion bags and CD34<sup>+</sup> cells per kg for this patient.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>20&nbsp;mL</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> OTHER</span></b></p>

</div>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>For autologous use only.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE LOT INFORMATION SHEET INCLUDED WITH EACH SHIPMENT FOR ONE
PATIENT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Zynteglo 1.2&#8209;20&nbsp;&nbsp;10<sup>6</sup>
cells/mL dispersion for infusion </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(betibeglogene
autotemcel)</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Zynteglo is a genetically modified
autologous CD34<sup>+</sup> cell enriched population that contains
haematopoietic stem cells transduced with lentiviral vector encoding the &#946;<sup>A&#8209;T87Q</sup>&#8209;globin
gene.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span style='font-family:"Times New Roman",serif'>3.</span></b><span
style='font-family:"Times New Roman",serif'> <b>DONATION AND PRODUCT
CODES</b></span></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>PATIENT INFORMATION</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Name (Last, First):</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Date of Birth
(DD/MM/YYYY):</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Weight at First Collection (kg): </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Patient ID:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4. BATCH
NUMBER, CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT, AND EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>INFORMATION ON SUPPLIED LOT(S)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>The
following lot(s) was manufactured and included in the shipment:</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=615
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.5pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Lot Number / COI ID </span></b></p>
  </td>
  <td width=93 valign=top style='width:69.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.5pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>DIN</span></b></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.5pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>(List all collections)</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Number
  of Infusion Bags</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Bag ID</span></b></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:2.0pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(List each infusion bag)</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:4.0pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Strength</span></b><span
  style='font-family:"Times New Roman",serif'> (&nbsp;10<sup>6</sup> cells/mL)</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>CD34<sup>+</sup> Cells</span></b><span
  style='font-family:"Times New Roman",serif'><br clear=all>
  (&nbsp;10<sup>6</sup> CD34<sup>+</sup> cells)</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Expiry Date</span></b></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>(DD/MM/YYYY)</span></p>
  </td>
 </tr>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=93 valign=top style='width:69.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=93 valign=top style='width:69.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=93 valign=top style='width:69.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=93 valign=top style='width:69.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:5.65pt;
  margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'> DOSE OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Total Number of Infusion Bags: __</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Dose:
{N.N}<span style='color:#2E74B5'> </span><span style='color:#2E74B5'> </span></span></b><span
style='font-family:"Times New Roman",serif'>10<sup>6</sup>&nbsp;CD34<sup>+</sup>
cells/kg </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>The minimum recommended dose of Zynteglo is
5.0&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup> cells/kg. In clinical
studies doses up to 20&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34+ cells/kg have been
administered.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span style='font-family:"Times New Roman",serif'>6.</span></b><span
style='font-family:"Times New Roman",serif'> <b>OTHER SPECIAL WARNING(S),
IF NECESSARY</b></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
name="_Hlk520301262"><span style='font-family:"Times New Roman",serif'>SAVE
THIS DOCUMENT AND PREPARE TO HAVE IT AVAILABLE AT THE TIME OF ZYNTEGLO
INFUSION.</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Read the package leaflet
before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>For autologous use only.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span style='font-family:"Times New Roman",serif'>7.</span></b><span
style='font-family:"Times New Roman",serif'> <b>SPECIAL STORAGE
CONDITIONS</b></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>INSTRUCTIONS FOR STORAGE
AND USE</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Store in the vapour
phase of liquid nitrogen at &#8804;-140C until ready for thaw and
administration. Keep infusion bag(s) in the metal cassette(s). Once thawed do
not re-freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;
padding:0in'><b><span style='font-family:"Times New Roman",serif'>8.</span></b><span
style='font-family:"Times New Roman",serif'> <b>SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</b></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>This medicine contains
genetically-modified cells. Unused medicine must be disposed of in compliance
with the local guidelines on handling human-derived material.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span style='font-family:"Times New Roman",serif'>9.</span></b><span
style='font-family:"Times New Roman",serif'> <b>NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</b></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>MARKETING AUTHORISATION HOLDER AND
NUMBER</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>bluebird bio (Netherlands) B.V.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Stadsplateau 7</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>WTC Utrecht</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>3521AZ Utrecht</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>The Netherlands</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>e-mail: </span><span
style='font-family:"Times New Roman",serif'>medinfo@bluebirdbio.com</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span style='font-family:"Times New Roman",serif'>10.</span></b><span
style='font-family:"Times New Roman",serif'> <b>MARKETING AUTHORISATION
NUMBER(S) </b></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>EU/1/19/1367/001</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.65pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span style='font-family:"Times New Roman",serif'>B.
PACKAGE LEAFLET</span></b></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Package
leaflet: Information for the patient or carer</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Zynteglo
1.2&#8209;20&nbsp;&nbsp;10<sup>6 </sup>cells/mL dispersion for infusion</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><span style='font-family:"Times New Roman",serif'>betibeglogene
autotemcel </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'><img border=0 width=21
height=18 id="Picture 1882439266" src="Zynteglo_clean_files/image003.png"
alt="BT_1000x858px"></span><span style='font-family:"Times New Roman",serif'>This
medicine is subject to additional monitoring. This will allow quick
identification of new safety information. You can help by reporting any side
effects you may get. See the end of section 4 for how to report side effects.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>Read all of this leaflet carefully
before you are given this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
none'><span style='font-family:"Times New Roman",serif'>You will be given a <b>Patient
Alert Card</b> which contains important safety information that you need to
know about your treatment with Zynteglo. You should carry the Patient Alert
Card with you at all times and show it to your doctor or nurse when you see
them or if you are admitted to the hospital.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>Keep this
leaflet. You may need to read it again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>If you have any
further questions, ask your doctor or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>If you get any
side effects, talk to your doctor or nurse.<span style='color:red'> </span>This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>Read the
Patient Alert Card carefully and follow the instructions on it. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>What
is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>1. What
Zynteglo is and what it is used for </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>2. What
you need to know before you are given Zynteglo</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>3. How
Zynteglo is given</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>4. Possible
side effects </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>5. How
to store Zynteglo </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>6. Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>1.</span></b><b><span
style='font-family:"Times New Roman",serif'> What Zynteglo is and what it
is used for</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Zynteglo</span><span
style='font-family:"Times New Roman",serif'> is used to treat a serious genetic
disease called transfusion&#8209;dependent beta&#8209;thalassaemia (TDT), which
includes the disease commonly known as beta&#8209;thalassaemia major, in people
12 years and older. People with this condition cannot make enough haemoglobin,
a protein in the blood that carries oxygen. More specifically, people with TDT
do not make enough of a part of the haemoglobin called beta-globin, due to a
gene defect. Because of this defect, people with TDT are anaemic and need
frequent blood transfusions to survive.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Zynteglo
is a type of medicine called gene therapy. It is made specifically for each
patient, using the patients own (also called autologous) blood stem cells.
Zynteglo works by adding functional copies of the beta-globin gene into these cells,
so that the patient can make enough beta-globin to increase total haemoglobin,
improve anaemia, and carry more oxygen around their body. This reduces or
eliminates the need for blood transfusions.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>2.</span></b><span
style='font-family:"Times New Roman",serif'> <b>What you need to know
before you are given Zynteglo</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>You must not be given Zynteglo if
you</span></b><span style='font-family:"Times New Roman",serif'>:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>are allergic to
any of the ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>are pregnant or
breast-feeding</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><a name="_Hlk817587"><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>have previously
received gene therapy of your blood stem cells</span></a></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>are allergic to
any of the ingredients in the medicines you will be given for mobilisation and
chemotherapy (see section 3).</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>Warnings and precautions </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Talk to your doctor before you are
given Zynteglo.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>Before treatment with Zynteglo, you will be given
medicines know as mobilisation medicine and chemotherapy medicine (see sections
3 and 4 for more information on these medicines, including possible side
effects).</span></p>

<p class=C-BodyText style='margin:0in;line-height:normal'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Before treatment with Zynteglo,
your doctor will perform tests to make sure your heart and liver are
functioning properly so you can be treated safely with Zynteglo. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Zynteglo</span><span
style='font-family:"Times New Roman",serif'> is made specifically for you,
using your own blood stem cells. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>After you have been treated with
Zynteglo, you will not be able to donate blood, organs, or tissues in the
future. This is because Zynteglo is a gene therapy medicine. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Adding a new gene into the DNA of
your blood stem cells could theoretically cause leukaemia or lymphoma, although
no patients have developed leukaemia or lymphoma in clinical trials with
Zynteglo. After treatment with Zynteglo, you will be asked to enrol in a
registry for at least 15 years in order to better understand the long-term
effects of Zynteglo. During the long-term follow-up, your doctor will monitor
you for any signs of leukaemia or lymphoma. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Zynteglo is prepared using parts of
the human immunodeficiency virus (HIV), which have been altered so that they
cannot cause HIV infection. The modified virus is used to insert a functional
beta-globin gene into your blood stem cells. Although this medicine will not
give you HIV infection, having Zynteglo in your blood may cause a false
positive HIV test result with some commercial tests that recognise a piece of
HIV used to make Zynteglo. If you test positive for HIV following treatment,
please contact your doctor or nurse. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Before receiving Zynteglo you will
be given chemotherapy in order to remove your existing bone marrow. If Zynteglo
cannot be administered after chemotherapy or if the modified stem cells do not
take hold (engraft) in your body, the doctor may give you an infusion of your
own original blood stem cells that were collected and stored before the
treatment started (see also section 3, How Zynteglo is given)<i>. </i></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>After you receive Zynteglo, you may
have a low number of platelets in your blood. This means that your blood may
not be able to clot as well as normal and you may be prone to bleeding. You
must get medical attention if you: </span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bump your head
or have a head injury</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>have symptoms
that could be from internal bleeding, such as unusual stomach or back pain, or
severe headache</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>have abnormal
bruising or bleeding (such as bruising without injury, blood in your urine,
stool, vomit, or cough up blood).</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Your doctor will tell you when your
platelet count has recovered to normal levels.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>Other medicines and Zynteglo </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Tell your doctor if you are taking,
have recently taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>You should not take hydroxyurea (a
medicine for blood disorders) or any medicines for HIV infection from at least
one month before you undergo mobilisation until at least 7 days after Zynteglo
infusion (see also section 3, How Zynteglo is given).</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>You should stop taking medicines to
remove iron from your body (so-called chelating agents: deferoxamine,
deferiprone and/or deferasirox) 7 days before you start the chemotherapy before
the infusion of Zynteglo (see section 3, How Zynteglo is given). Your doctor
will advise you if and when you should start taking these medicines after
Zynteglo infusion. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Talk to your doctor if you need to
have any vaccinations. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><b><span style='font-family:"Times New Roman",serif'>Pregnancy,
breast-feeding and fertility</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>If you are pregnant or
breast-feeding, think you may be pregnant or are planning to have a baby, tell
your doctor before you are given this medicine.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>If you are a woman, you will be
given a pregnancy test before starting mobilisation, before you are given
chemotherapy, and before Zynteglo treatment in order to confirm that you are
not pregnant.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Women who could become pregnant and
men capable of fathering a child must start using a reliable method of
contraception from before their blood stem cells are collected and continue
until at least 6 months after receiving Zynteglo. Reliable methods of contraception
include intra-uterine device or a combination of oral contraceptive (also know
as the pill) and condoms.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>The added gene from Zynteglo will
not be passed on to your children. Your children are still at risk of
inheriting your original beta&#8209;globin gene.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>You should not be given Zynteglo if
you are breast-feeding. It is not known whether the ingredients of Zynteglo can
pass into breast milk.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>It may no longer be possible for
you to become pregnant or father a child after receiving chemotherapy medicine.
If you are concerned about having children, you should discuss this with your
doctor before treatment. Options may include providing reproductive material
for storage in a tissue bank to use at a later time. For men, this may be sperm
or testicular tissue. For women, this may be eggs (oocytes) or ovarian tissue.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Driving
and using machines</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><a name="_Hlk32575891"><span
style='font-family:"Times New Roman",serif'>Zynteglo has no influence on the
ability to drive or use machines. However, the mobilisation and chemotherapy medicines
may cause dizziness and fatigue. Avoid driving or using machines if you feel
dizzy, tired or unwell.</span></a></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Sodium
content</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>This
medicine contains 391&#8209;1564&nbsp;mg sodium (main component of
cooking/table salt) in each dose. This is equivalent to <span style='color:
black'>20&#8209;78% </span>of the recommended maximum daily dietary intake of sodium
for an adult.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;page-break-after:avoid'><b><span
style='font-family:"Times New Roman",serif'>3.</span></b><b><span
style='font-family:"Times New Roman",serif'> How Zynteglo is given</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Zynteglo
is given by a drip (infusion) into a vein. It can only be given in a
specialised hospital by doctors who are experienced in treating patients with
TDT, administering bone marrow transplants, and using gene therapy medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Zynteglo
can only be made if enough of the right kind of blood stem cells can be
collected from your blood (CD34<sup>+</sup> blood stem cells). Approximately 2
months before treatment with Zynteglo, you will be given a mobilisation
medicine that will move your blood stem cells from your bone marrow into your
blood stream. The blood stem cells can then be collected by a machine that
separates blood components (apheresis machine). It may take more than 1 day to
collect enough blood stem cells to make Zynteglo and to store as replacement
cells if Zynteglo cannot be given or does not work.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
   0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Time</span></b></p>
   </td>
   <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
   0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>What
   happens</span></b></p>
   </td>
   <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
   0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Why</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Approximately
  2&nbsp;months before Zynteglo infusion</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Mobilisation
  medicine is given</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>To
  move the blood stem cells from your bone marrow into your blood stream.</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Approximately
  2&nbsp;months before Zynteglo infusion</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Blood
  stem cells are collected </span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>To
  make Zynteglo and to serve as replacement cells if needed.</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>At
  least 6&nbsp;days before Zynteglo infusion</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>A
  chemotherapy medicine is given for 4&nbsp;days in a hospital</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>To
  prepare your bone marrow for treatment with Zynteglo.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Start
  of Zynteglo treatment</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Zynteglo
  is given by a drip (infusion) into a vein. This will take place in a hospital
  and will take less than 30 minutes for each infusion bag. The number of bags
  will vary by patient.</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>To
  add blood stem cells containing functional copies of the beta-globin into
  your bone marrow.</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif'>After Zynteglo
  infusion</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif'>You will remain in
  the hospital for approximately 3&#8209;6 weeks</span></p>
  </td>
  <td width=202 valign=top style='width:151.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span style='font-family:"Times New Roman",serif'>To recover and be monitored
  until your doctor is satisfied that it is safe for you to leave the hospital.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><a
name="_Hlk512253721"><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></a></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>4.</span></b><b><span
style='font-family:"Times New Roman",serif'> Possible side effects</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Like
all medicines, this medicine can cause side effects, although not everybody
gets them. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Some
side effects observed in clinical studies with Zynteglo are related to
mobilisation and blood stem cell collection or to the chemotherapy medicine
used to prepare your bone marrow for treatment with Zynteglo. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>You
should discuss possible side effects due to the mobilisation medicines and
chemotherapy medicine with your doctor. You should also read the package
leaflets for these medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><u><span style='font-family:"Times New Roman",serif'>Mobilisation
and blood stem cell collection</span></u></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Most
of these side effects occur during or within a few days after mobilisation and
blood stem cell collection but can occur later. Tell your doctor immediately if
side effects become severe or serious. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Very
common side effects </span></b><span style='font-family:"Times New Roman",serif'>(may
affect more than 1 in 10 people)</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><a name="_Hlk542621"><span style='font-family:"Times New Roman",serif'>a
     low level of blood platelets, which may reduce the ability of blood to
     clot</span></a></li>
</ul>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bone pain</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>numbness and
     pain in hands and feet</span></li>
</ul>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>feeling sick
(nausea)</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>headache</span></li>
</ul>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low blood
calcium level</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Common
side effects </span></b><span style='font-family:"Times New Roman",serif'>(may
affect up to 1 in 10 people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><a name="_Hlk540035"><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bleeding </span></a></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low oxygen
level in blood </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low blood
pressure</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>abdominal pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>back pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bone or muscle
pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>chest pain or
discomfort</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>other pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>agitation </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>abnormal blood
test results (decrease in magnesium and potassium, too much citrate, or
increase in white blood cells)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>abnormal heart
rhythm </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bruising,
bleeding or pain from catheter or injection site</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>injection site
reaction </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bruising </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>dizziness,
tiredness</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>head discomfort</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>excessive
sweating</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>flu like illness</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>lip swelling</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>tingling or
numbness of the hands, feet, or mouth</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>fever</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>rash</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>enlarged spleen
which may result in pain in your upper left belly or left shoulder</span></p>

<p class=MsoListParagraphCxSpLast style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>vomiting </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><u><span style='font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><u><span style='font-family:"Times New Roman",serif'>Chemotherapy
medicine</span></u></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Tell
your doctor immediately </span></b><span style='font-family:"Times New Roman",serif'>if
you get any of the following side effects after receiving chemotherapy
medicine. They usually happen within the first few days and several weeks after
receiving chemotherapy medicine, but can also develop much later.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Very
common </span></b><span style='font-family:"Times New Roman",serif'>(may affect
more than 1 in 10 people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>Pain in the
right upper abdomen under the ribs, yellowing of eyes or skin, rapid weight
gain, swelling of arms, legs and abdomen, and trouble breathing. These may be
signs of a serious liver condition called veno-occlusive disease.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>Prolonged
bleeding or bleeding without injury such as nosebleeds, bleeding from gums, or
vaginal bleeding.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Other
possible side effects</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Tell
your doctor immediately if side effects become severe or serious.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Very
common side effects </span></b><span style='font-family:"Times New Roman",serif'>(may
affect more than 1 in 10 people)</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><a name="_Hlk543255"><span style='font-family:"Times New Roman",serif'>low
     level of red and white blood cells, sometimes with a fever</span></a></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>increase of
     certain enzymes in the blood which may indicate a problem with your liver</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>a low level of
     blood platelets, which may reduce the ability of blood to clot</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>unusual hair
     loss or thinning</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>stomach pain, constipation,
     diarrhoea</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>feeling sick
     (nausea), being sick (vomiting)</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>fever</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>soreness of the
     mouth</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>inflammation of
     the throat</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>dark patches on
     skin</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>soreness of the
     rectum area</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>trouble sleeping</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>decreased
     appetite</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>headache</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>tiredness</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>itchy skin</span></li>
</ul>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>soreness and swelling
of the digestive tract lining which runs from the mouth to the anus</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:.5in;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Common
side effects </span></b><span style='font-family:"Times New Roman",serif'>(may
affect up to 1 in 10 people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>life-threatening
inflammatory response to an infection along with low white blood cell count</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>heart failure</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>infections
which may make you feel warm, chilly, or sweaty</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>mass in the
lungs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>enlarged
abdomen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>enlarged liver</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>difficulty
breathing </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>abdominal pain</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>bleeding or
bruising </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>blood in urine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>yellowing of
eyes or skin</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>small tear in
tissue that lines the anus</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>dizziness, or
sensation of feeling off balance or like the room is spinning</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>memory problems
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>anxiety </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>positive test
for Aspergillus (lung disease caused by fungus)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>changes and
abnormalities in heart rhythm</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>pain, including
in back, bone, skin, limbs, anus, or muscles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>vaginal yeast
infection</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>heartburn</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>inflammation of
the gallbladder</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>gallstones</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>cough</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>abnormal sense
of taste or loss of taste</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>difficulty
swallowing</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>swelling of the
face</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>feeling cold</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>excess water in
the body</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>inflammation or
infection of hair follicles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>decrease in
speed of air leaving your lungs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>stomach
discomfort with nausea and vomiting</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>inflammation in
the digestive tract</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>gum disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>piles
(haemorrhoids)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>hiccups</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low blood
pressure</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low body
temperature</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low oxygen
level in blood</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>pain in mouth,
throat or larynx (voice box)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>lack of energy</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>irregular
menstruation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>loss of
function or decreased function of your ovaries or testes</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>premature
menopause </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>spots on skin
from bleeding under the skin</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>skin that is
discoloured, blotchy, or darker or lighter than normal </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>fluid in or
around the lung</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>hot flush</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>increased
frequency of urination</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>dry, itchy skin
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>dry lips</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>rash sometimes
with lesions or pus </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>inflamed skin
lesions</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>skin
abrasion/scrape</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>sweat gland
disorder</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>transfusion
reaction</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>weight
decreased</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>abnormal liver
tests</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>increased
concentration of haemoglobin in cells</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span lang=DE style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=DE style='font-family:"Times New Roman",serif'>changes
in magnesium, calcium, potassium, phosphate, albumin, protein, sodium in blood</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>increase in
blood test for inflammation</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>excess acid in
the body not removed by the kidneys</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>increase or
decrease in white blood cells</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>low number of
immature (not fully developed) red blood cells </span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>increase in
female hormones</span></p>

<p class=MsoListParagraph style='margin-bottom:0in;text-indent:-.25in;
line-height:normal'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>decreased
testosterone</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><u><span style='font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal;page-break-after:avoid'><b><u><span
style='font-family:"Times New Roman",serif'>Zynteglo</span></u></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Most
side effects occur during or within a few days after treatment with Zynteglo
but can occur later. </span><span style='font-family:"Times New Roman",serif'>Tell
your doctor immediately if side effects become severe or serious.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Very
common side effects </span></b><span style='font-family:"Times New Roman",serif'>(may
affect more than 1 in 10 people)</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>stomach pain</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Common
side effects </span></b><span style='font-family:"Times New Roman",serif'>(may
affect up to 1 in 10 people)</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>low level of
     blood platelets, which may reduce the ability of blood to clot</span></li>
 <li class=MsoNormal style='margin-right:-1.45pt;margin-bottom:0in;line-height:
     normal'><span style='font-family:"Times New Roman",serif'>low level of
     white blood cells</span></li>
</ul>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>shortness of
breath</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>chest pain not
due to a heart problem</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>flushing
(redness and warmth of skin)</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>pain in legs</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-1.45pt;
margin-bottom:0in;margin-left:.5in;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal;page-break-after:avoid'><b><span
style='font-family:"Times New Roman",serif'>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>If
you get any side effects, talk to your doctor or nurse. This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:lightgrey'>the national reporting
system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-family:"Times New Roman",serif;background:lightgrey'>Appendix V</span></a><span
style='font-family:"Times New Roman",serif;background:lightgrey'>.</span><span
style='font-family:"Times New Roman",serif'> By reporting side effects you can
help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
style='font-family:"Times New Roman",serif'>5.</span></b><span
style='font-family:"Times New Roman",serif'> <b>How to store Zynteglo</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>This
information is intended for doctors only.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>As
this medicine will be given by a qualified doctor, they are responsible for the
correct storage of the medicine before and during its use, as well as for its
correct disposal. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Keep
this medicine out of the sight and reach of children. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Do
not use this medicine after the expiry date which is stated on the outer
container label(s) and infusion bag label(s).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>Store
at &#8804;-140C for up to a year. Do not thaw the product until it is ready to
be used. Once thawed store at room temperature (20C&#8209;25C) and use within
4 hours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>This
medicine contains genetically-modified cells. Unused medicine must be disposed
of in compliance with the local guidelines on handling human-derived material. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>6.</span></b><span
style='font-family:"Times New Roman",serif'> <b>Contents of the pack and
other information</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>What
Zynteglo contains </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>The active
substance of Zynteglo consists of your own blood stem cells that contain
functional copies of the beta-globin gene that can be measured in your blood.
The concentration is 1.2&#8209;20&nbsp;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup>
cells (blood stem cells) per millilitre.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>The other ingredients
are a solution used to preserve frozen cells and sodium chloride. See section
2, Sodium content.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>What
Zynteglo looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
name="_Hlk511315491"><span style='font-family:"Times New Roman",serif'>Zynteglo
is a clear to slightly cloudy, colourless to yellow or pink dispersion of cells</span></a><span
style='font-family:"Times New Roman",serif'> that is supplied in one or more
clear infusion bags, each packed in a transparent pouch inside a closed metal
container. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Your name and date of birth, as
well as coded information identifying you as the patient, are printed onto each
infusion bag and each metal container.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>bluebird bio (Netherlands)
B.V.&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=NL
style='font-family:"Times New Roman",serif'>Stadsplateau 7&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=NL
style='font-family:"Times New Roman",serif'>WTC Utrecht&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=NL
style='font-family:"Times New Roman",serif'>3521AZ Utrecht&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=NL
style='font-family:"Times New Roman",serif'>The Netherlands&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
href="mailto:medinfo@bluebirdbio.com"><span lang=PT style='font-family:"Times New Roman",serif'>medinfo@bluebirdbio.com</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=PT
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span lang=PT style='font-family:"Times New Roman",serif'>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span lang=PT
style='font-family:"Times New Roman",serif'>Minaris Regenerative Medicine GmbH </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Haidgraben 5</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>85521 Ottobrunn</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Germany</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>For
any information about this medicine, please contact the local representative of
the Marketing Authorisation Holder:<span style='color:red'> </span></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
  name="_Hlk1050692"><b><span lang=DE style='font-family:"Times New Roman",serif'>Deutschland</span></b></a></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=DE style='font-family:"Times New Roman",serif'>bluebird bio (Germany)
  GmbH</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=DE style='font-family:"Times New Roman",serif'>Tel: +49 (0) 893 803 7456
  (0800 181 0702)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  lang=ES style='font-family:"Times New Roman",serif'>Italia</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=ES style='font-family:"Times New Roman",serif'>bluebird bio (Italy)
  S.r.l.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=DE style='font-family:"Times New Roman",serif'>Tel: </span><span
  style='font-family:"Times New Roman",serif'>+39 029 475 9755 (800 728 026)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=NL style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>France</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>bluebird bio (France) SAS</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
  none'><span style='font-family:"Times New Roman",serif'>Tl: +33 (0)1 85 14
  97 89 (0800 914 510)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  lang=NL style='font-family:"Times New Roman",serif'>Nederland</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=NL style='font-family:"Times New Roman",serif'>bluebird bio
  (Netherlands) B.V.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>Tel: +</span><span lang=DE
  style='font-family:"Times New Roman",serif'>31 (0) 303 100 450</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>Belgi/Belgique/Belgien,
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;, &#268;esk
  republika, Danmark, Eesti, &#917;&#955;&#955;&#940;&#948;&#945;, Espaa, </span></b><b><span
  style='font-family:"Times New Roman",serif'>Hrvatska, Ireland, sland,
  &#922;&#973;&#960;&#961;&#959;&#962;, Latvija, Lietuva, Luxembourg/Luxemburg,
  Magyarorszg, Malta, Norge, sterreich, Polska, Portugal, Romnia, Slovenija,
  Slovensk republika, Suomi/Finland, Sverige</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>bluebird bio (Netherlands) B.V.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>Tl/Tel/Te&#1083;/Tlf/&#932;&#951;&#955;/Smi/Puh:
  </span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>+31 (0) </span><span lang=DE
  style='font-family:"Times New Roman",serif'>303 100 450</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><a
  href="mailto:medinfo@bluebirdbio.com"><span lang=DE style='font-family:"Times New Roman",serif'>medinfo@bluebirdbio.com</span></a><span
  lang=DE style='font-family:"Times New Roman",serif'> </span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif'>United Kingdom</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>bluebird bio (UK) Limited</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>Tel: +44 (0) 207 660 0754</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>(0800-069-8046)</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><b><span style='font-family:"Times New Roman",serif'>This
leaflet was last revised in &lt;</span></b><span style='font-family:"Times New Roman",serif'>{<b>MM/YYYY</b>}&gt;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>This
medicine has been given conditional approval. This means that there is more
evidence to come about this medicine. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>The
European Medicines Agency will review new information on this medicine at least
every year and this leaflet will be updated as necessary.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span><u><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:blue'>http://www.ema.europa.eu</span></u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&lt;, and on the website of {name
of MS Agency (link)}&gt;.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>This
leaflet is available in all EU/EEA languages on the European Medicines Agency
website.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>-----------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-2.0pt;line-height:normal;page-break-after:avoid'><b><span
style='font-family:"Times New Roman",serif'>The following information is
intended for healthcare professionals only: </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-2.0pt;line-height:normal;page-break-after:avoid'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Zynteglo is shipped from the
manufacturing facility to the infusion centre storage facility in a
cryoshipper, which may contain multiple metal cassettes intended for a single
patient. Each metal cassette contains one infusion bag with Zynteglo. A patient
may have multiple infusion bags. The infusion bag(s) must be kept inside the
metal cassette(s) until ready to thaw and use.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Confirm that Zynteglo is printed on
the infusion bag(s). Confirm that patient identity matches the unique patient
information located on the infusion bag(s) and metal cassette(s) prior to
infusion.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Account for all infusion bags and
confirm each infusion bag of Zynteglo is within the expiry date using the
accompanying Lot Information Sheet. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Inspect each infusion bag for any
breaches of integrity before thawing and infusion. If an infusion bag is
compromised, follow the local guidelines on handling human-derived material and
contact bluebird bio immediately.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Zynteglo is intended solely for
autologous use. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>After carefully removing the outer
metal container, thaw each infusion bag at 37C in a water bath or dry bath for
approximately 2&#8209;4&nbsp;minutes. Do not overthaw the medicinal product. Do
not leave the medicinal product unattended and do not submerge the infusion
ports if thawed in a water bath. After thaw, mix the medicinal product gently
by massaging the infusion bag until all of the contents are uniform. Expose the
sterile port on the infusion bag by tearing off the protective wrap covering
the port. Access the infusion bag and infuse per the administration sites
standard procedures for administration of cell therapy products. Do not use an
in-line blood filter or an infusion pump. Do not sample, alter, or irradiate
the medicinal product. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Administer each infusion bag via
intravenous infusion over a period of less than 30&nbsp;minutes. If more than
one infusion bag is provided, administer each infusion bag completely before
proceeding to thaw and infuse the next bag. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Zynteglo must not be re&#8209;frozen.
Infuse as soon as possible and no more than 4&nbsp;hours after thawing. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Flush all Zynteglo remaining in the
infusion bag and any associated tubing with at least 50&nbsp;mL of 0.9% sodium
chloride solution to ensure as many cells as possible are infused into the
patient.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>This medicinal product contains
genetically-modified cells. Local guidelines on handling and waste of human-derived
material applicable for such products should be followed.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Healthcare professionals handling
Zynteglo should take standard precautions (wearing gloves, protective clothing
and eye protection) to avoid potential transmission of infectious diseases.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>Work surfaces and material which
have potentially been in contact with Zynteglo must be decontaminated with a
viricidal disinfectant according to the manufacturer's instructions. </span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

</div>

</body>

</html>
